CINXE.COM

<!DOCTYPE html> <html lang="en-us"> <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta charset="utf-8" /><meta http-equiv="X-UA-Compatible" content="IE=edge" /><meta name="viewport" content="width=device-width, initial-scale=1" /><title> Peer-Reviewed Publications - Creative Biolabs </title> <base href="/" /> <link rel="icon" href="static/images/favicon.png" type="image/x-icon" />  <link rel="stylesheet" type="text/css" href="static/css/key.css?t=D20190703" /><link rel="preconnect" href="https://www.googletagmanager.com" /><link rel="preconnect" href="https://bat.bing.com" /><link rel="preconnect" href="https://www.cblcdn.com" /><link rel="canonical" href="https://www.creative-biolabs.com/Peer-reviewed-Publications.html" /> <link rel="stylesheet" type="text/css" href="static/css/style-services.min.css?t=D20190703" /> <link rel="stylesheet" type="text/css" href="static/css/style-podcast.min.css?t=D20190703" /> <link rel="stylesheet" type="text/css" href="static/css/style-inquiry.min.css?t=D20190703" /> <style> .inquiry_arera { padding-top: 30px; padding-bottom: 30px; background-color: #f2f2f2; display: block; } .inquiry_arera div[class*="col"] { padding-top: 5px; padding-bottom: 5px; } span.inq-icon-but { background: linear-gradient(to right, #c45160,#f0924c ) !important; color: #fff; text-align: center; font-weight: bold; padding:7px 50px 7px 10px; display: inline-block; cursor: pointer; position: relative; } span.inq-icon-but::after{ content:""; position: absolute; background-image: url('../static/images/5-120601154058-50.gif'); top:6px; right:10px; width:30px; height:30px; background-repeat: no-repeat; background-position: center; } .inqpagebut span.inq-icon-but::after{ content:"→" !important; background-image:none !important; top:8px !important; font-size:20px; } .inqpagebut{display: block;padding-top:30px !important;padding-bottom:30px !important; text-align: center;} span.inq-icon-but:hover { background-color: linear-gradient(to right, #f0924c,#c45160 ) !important; color: #fff; } .inq_bg { position: fixed; top: 0px; left: 0; background-color: rgba(0,0,0,0.7); width: 100%; height: 100%; z-index: 1100; align-items: center; justify-content: center; display: none; } .inq_bg .inqfor { background-color: #fff; padding: 20px; border-radius: 10px; position: relative; margin: 4% auto auto auto; } .inq_bg .inqfor .clos { width: 40px; height: 40px; top: 0; right: 0px; position: absolute; display: inline-block; line-height: 40px; text-align: center; font-size: 24px; z-index: 1000; cursor: pointer; } @media (min-width:769px) { .inq_bg .inqfor { width: 60%; } .inqfor div[class*="col-md"]:nth-child(1),.inqfor div[class*="col-md"]:nth-child(2),.inqfor div[class*="col-md"]:nth-child(3){ width:33.3% !important; } } @media (max-width:768px) { .inq_bg .inqfor { width: 90%; overflow-y: scroll; } } </style> <script>dataLayer = [{"ip":"8.222.208.146","c_session_id":"C1CF698B84321D399DC6EA71CF4FEA17","c_user_id":"C1CF698B84321D399DC6EA71CF4FEA17"}];</script>  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MD8987');</script> <meta name="description" content="Within the last 10 years, Creative Biolabs has provided high-quality service to numerous customers." /><meta name="keywords" content="Creative Biolabs, Custom Services, published, peer-reviewed, academia, industry, service, patent" /></head> <body>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MD8987&ip=8.222.208.146&c_session_id=C1CF698B84321D399DC6EA71CF4FEA17&c_user_id=C1CF698B84321D399DC6EA71CF4FEA17" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div class="autoheader"> <div class="topad_pic" style="display: block;">  <a href="https://events.creative-biolabs.com" id="ad_exhibition" rel="nofollow" aria-label="Meet Us at the Upcoming Events"> <div class="source-img-box"> </div> </a> </div> <div id="header"> <a href="/"> <img src="static/images/biolabs.com-1921x690-color.png" srcset="static/images/biolabs.com-1921x690-color.webp 1x, static/images/biolabs.com-1921x690-color.webp 2x, static/images/biolabs.com-1921x690-color.webp 3x" id="logo" width="120" height="60" alt="Creative biolabs"></a> <div class="navMenu"> MENU SEARCH </div> </div> </div> <div class="nav_bg" style="background-color: rgba(0,0,0,0.6);"></div> <div class="menuShow"> Close <div class="mennav"> <ul style="position: relative;"> <li> Discovery <div class="secondMenu"> <div class="second-menu-area-box"> <ul style="margin-top:0;">  <li class="col-md-8 col-lg-8 col-sm-8"> <ul class="navi-menu-2 MenuList"><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="By Technology">By Technology</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/phage-display-service.html" title="Phage Display based Binder Discovery">Phage Display based Binder Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/phage-display-library-construction.html" title="Phage Display Library Construction">Phage Display Library Construction</a></li><li class="navi-menu-li-4"><a href="/phage-display-library-screening.html" title="Phage Display Library Screening">Phage Display Library Screening</a></li></ul></li><li class="navi-menu-li-3"><a href="/yeast-display-services.html" title="Yeast Display based Binder Discovery">Yeast Display based Binder Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/yeast-display-library-construction-services.html" title="Yeast Display Library Construction">Yeast Display Library Construction</a></li><li class="navi-menu-li-4"><a href="/yeast-display-library-screening-services.html" title="Yeast Display Library Screening">Yeast Display Library Screening</a></li></ul></li><li class="navi-menu-li-3"><a href="/premade-library-based-binder-discovery-services.html" title="Premade Library based Binder Discovery">Premade Library based Binder Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="javascript:void(0)" title="Premade Library Licensing">Premade Library Licensing</a><ul class="navi-menu-5 three_menu"><li class="navi-menu-li-5"><a href="/premade-human-and-mouse-antibody-libraries.html" title="Premade Antibody Library">Premade Antibody Library</a></li><li class="navi-menu-li-5"><a href="/premade-phage-display-peptide-libraries.html" title="Premade Peptide Library">Premade Peptide Library</a></li><li class="navi-menu-li-5"><a href="/Premade-single-domain-antibody-library.html" title="Premade SdAb Library">Premade SdAb Library</a></li><li class="navi-menu-li-5"><a href="/Immunized-Human-Antibody-Library.html" title="Immune Human Antibody Library">Immune Human Antibody Library</a></li></ul></li><li class="navi-menu-li-4"><a href="/premade-phage-display-antibody-library-screening-service.html" title="Premade Antibody Library Screening">Premade Antibody Library Screening</a></li><li class="navi-menu-li-4"><a href="/premade-single-domain-antibody-library-screening-service.html" title="Premade Single Domain Antibody (SdAb) Library Screening">Premade Single Domain Antibody (SdAb) Library Screening</a></li><li class="navi-menu-li-4"><a href="/premade-phage-display-peptide-library-screening-service.html" title="Premade Peptide Library Screening">Premade Peptide Library Screening</a></li></ul></li><li class="navi-menu-li-3"><a href="/Native-TM-Antibody-Discovery-Service.html" title="Single B Cell Sorting based Antibody Discovery">Single B Cell Sorting based Antibody Discovery</a></li><li class="navi-menu-li-3"><a href="/custom-antibody-development.html" title="Hybridoma based Antibody Discovery">Hybridoma based Antibody Discovery</a></li><li class="navi-menu-li-3"><a href="/Human-Antibody-Production-from-Transgenic-Mice.html" title="Transgenic Mice based Human Antibody Discovery">Transgenic Mice based Human Antibody Discovery</a></li><li class="navi-menu-li-3"><a href="/biomolecular-interaction-analysis-services.html" title="Biomolecular Interaction based Binder Discovery">Biomolecular Interaction based Binder Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/yeast-two-hybrid-y2h-service.html" title="Yeast Two-Hybrid (Y2H)">Yeast Two-Hybrid (Y2H)</a></li><li class="navi-menu-li-4"><a href="/bacterial-two-hybrid-b2h-service.html" title="Bacterial Two-Hybrid (B2H)">Bacterial Two-Hybrid (B2H)</a></li></ul></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="By Binder">By Binder</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/sdab-single-domain-antibody.html" title="Single Domain Antibody (SdAb) Discovery">Single Domain Antibody (SdAb) Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/single-domain-antibody-library-service.html" title="SdAb Library Construction & Screening">SdAb Library Construction & Screening</a></li><li class="navi-menu-li-4"><a href="/human-or-humanized-sdab-production.html" title="Human/Humanized SdAb Discovery">Human/Humanized SdAb Discovery</a></li><li class="navi-menu-li-4"><a href="/bispecific-sdab-production.html" title="Bispecific SdAb Discovery">Bispecific SdAb Discovery</a></li></ul></li><li class="navi-menu-li-3"><a href="/immune-antibody-library-services.html" title="Monoclonal Antibody Discovery">Monoclonal Antibody Discovery</a></li><li class="navi-menu-li-3"><a href="/discovery-services.html" title="Polyclonal Antibody Discovery">Polyclonal Antibody Discovery</a></li><li class="navi-menu-li-3"><a href="/Engineered-Protein-Scaffold-Library-Construction-Service.html" title="Scaffold Discovery">Scaffold Discovery</a></li><li class="navi-menu-li-3"><a href="/Magic-Bioactive-Peptides-Discovery-Service.htm" title="Peptide Discovery">Peptide Discovery</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="By Target">By Target</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/membrane-protein-service.html" title="Membrane Protein Specific Antibody Discovery">Membrane Protein Specific Antibody Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/membrane-protein-preparation-as-antigen-for-antibody-discovery.html" title="Membrane Protein Antigen Preparation">Membrane Protein Antigen Preparation</a></li><li class="navi-menu-li-4"><a href="/MemProArt-TM-anti-GPCR-Antibody-Production.html" title="GPCR Specific Antibody Discovery">GPCR Specific Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/MemProArt-TM-anti-Ion-Channel-Antibody-Production.html" title="Ion Channel Specific Antibody Discovery">Ion Channel Specific Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/MemProArt-TM-anti-transporter-Antibody-Production.html" title="Transporter Specific Antibody Discovery">Transporter Specific Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/sdab-discovery-against-membrane-proteins-by-dna-immunization.html" title="Membrane Protein Specific Single Domain Antibody (SdAb) Discovery">Membrane Protein Specific Single Domain Antibody (SdAb) Discovery</a></li></ul></li><li class="navi-menu-li-3"><a href="/Custom-antibody-services-for-post-translational-modification-specific-antibody-discovery.html" title="Post-Translational Modification (PTM) Specific Antibody Discovery">Post-Translational Modification (PTM) Specific Antibody Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/Phosphorylation-Specific-Antibody-Production-Services.html" title="Phosphorylation Specific Antibody Discovery">Phosphorylation Specific Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/Acetylation-Specific-Antibody-Production-Services.html" title="Acetylation Specific Antibody Discovery">Acetylation Specific Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/Methylation-Specific-Antibody-Production-Services.html" title="Methylation Specific Antibody Discovery">Methylation Specific Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/Ubiquitination-Specific-Antibody-Production-Service.html" title="Ubiquitination Specific Antibody Discovery">Ubiquitination Specific Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/fatty-acylation-specific-antibody-production-services.html" title="Fatty Acylation (Myristoylation, Palmitoylation) Specific Antibody Discovery">Fatty Acylation (Myristoylation, Palmitoylation) Specific Antibody Discovery</a></li></ul></li><li class="navi-menu-li-3"><a href="/Production-of-Anti-idiotype-Antibody.html" title="Idiotype Specific Antibody Discovery">Idiotype Specific Antibody Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/Anti-Idiotypic-Antibodies-Production-service-detecting-FREE-antibodies.html" title="FREE Antibody recognized Anti-ID Antibody Discovery">FREE Antibody recognized Anti-ID Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/Anti-Idiotypic-Antibodies-Prodution-detecting-TOTAL-antibodiese.html" title="TOTAL Antibody recognized Anti-ID Antibody Discovery">TOTAL Antibody recognized Anti-ID Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/Anti-Idiotypic-Antibodies-Production-service-detecting-BOUND-antibodies.html" title="BOUND Antibody recognized Anti-ID Antibody Discovery">BOUND Antibody recognized Anti-ID Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/Anti-Idiotypic-Antibodies-Production-service-detecting-T-cell-receptors.html" title="T Cell Receptor recognized Anti-ID Antibody Discovery">T Cell Receptor recognized Anti-ID Antibody Discovery</a></li><li class="navi-menu-li-4"><a href="/camel-anti-idiotypic-antibodies-sdabs-production-service.html" title="Idiotype Specific Single Domain Antibody (SdAb) Discovery">Idiotype Specific Single Domain Antibody (SdAb) Discovery</a></li></ul></li><li class="navi-menu-li-3"><a href="/anti-hapten-antibody-development-service.html" title="Hapten Specific Antibody Discovery">Hapten Specific Antibody Discovery</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="By Application">By Application</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="javascript:void(0)" title="Stable Binder Discovery">Stable Binder Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/thermal-stable-mabs-discovery-services.html" title="Thermal Stable mAb Discovery">Thermal Stable mAb Discovery</a></li><li class="navi-menu-li-4"><a href="/Thermal-Stable-scFv-Fab-Screening.html" title="Thermal Stable ScFv/Fab Discovery">Thermal Stable ScFv/Fab Discovery</a></li><li class="navi-menu-li-4"><a href="/thermal-stable-vhh-screening.html" title="Thermal Stable SdAb Discovery">Thermal Stable SdAb Discovery</a></li></ul></li><li class="navi-menu-li-3"><a href="/ph-sensitive-biomolecules-discovery-services.html" title="pH-Sensitive Binder Discovery">pH-Sensitive Binder Discovery</a></li><li class="navi-menu-li-3"><a href="/Screening-for-Internalizing-Antibodies-and-Peptides.html" title="Internalizing Antibody Discovery">Internalizing Antibody Discovery</a></li><li class="navi-menu-li-3"><a href="/Super-TM-Intrabody-Generation.html" title="Intrabody Discovery">Intrabody Discovery</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/intrabody-discovery-service.html" title="SdAb based Intrabody Discovery">SdAb based Intrabody Discovery</a></li></ul></li><li class="navi-menu-li-3"><a href="/Agonistic-Antibody-Discovery-Service.html" title="Agonistic/Antagonistic Antibody Discovery">Agonistic/Antagonistic Antibody Discovery</a></li></ul></li></ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> Services Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-1.jpg" srcset="static/images/Solutions-menu-lights-pic-1.webp 1x" width="201" height="131" loading="lazy"><a href="discovery-services.html" class="bannerbutton">Discovery Services</a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-2.jpg" srcset="static/images/Solutions-menu-lights-pic-2.webp 1x" width="201" height="131" loading="lazy"><a href="engineering-services.html" class="bannerbutton"> Engineering Services </a> </li> </ul> </li> </ul> </div> </div> </li> <li> Characterization <div class="secondMenu"> <div class="second-menu-area-box"> <ul style="margin-top:0;">  <li class="col-md-8 col-lg-8 col-sm-8"> <ul class="navi-menu-2 MenuList"><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="Binding Analysis">Binding Analysis</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/Antibody-Affinity-Measurement.html" title="Affinity Measurement">Affinity Measurement</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/Affinity-Measurement-Services-for-Specific-Antibodies.html" title="Antibody Affinity Measurement">Antibody Affinity Measurement</a></li><li class="navi-menu-li-4"><a href="/Membrane-Proteins-Affinity-Measurement.html" title="Membrane Protein Affinity Measurement">Membrane Protein Affinity Measurement</a></li><li class="navi-menu-li-4"><a href="/Affinity-Measurement-Services-for-Small-Molecules.html" title="Small Molecule Affinity Measurement">Small Molecule Affinity Measurement</a></li></ul></li><li class="navi-menu-li-3"><a href="/precision-paratope-mapping-service.htm" title="Paratope Mapping">Paratope Mapping</a></li><li class="navi-menu-li-3"><a href="/Monoclonal-Antibody-Epitope-Binning.html" title="Epitope Binning">Epitope Binning</a></li><li class="navi-menu-li-3"><a href="/cremap.html" title="Epitope Mapping">Epitope Mapping</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/cremap-b-cell-epitope-mapping-service.html" title="B Cell Epitope Mapping">B Cell Epitope Mapping</a></li><li class="navi-menu-li-4"><a href="/cremap-t-cell-epitope-discovery-service.html" title="T Cell Epitope Discovery">T Cell Epitope Discovery</a></li></ul></li><li class="navi-menu-li-3"><a href="/high-throughput-membrane-protein-array-screening-services.html" title="Antibody Off-Target Identification & Specificity Profiling">Antibody Off-Target Identification & Specificity Profiling</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="Sequence Analysis">Sequence Analysis</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/next-generation-antibody-sequencing.html" title="De Novo Sequencing">De Novo Sequencing</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/De-Novo-Human-Humanized-Antibody-Sequencing-Service.html" title="Human/Humanized Antibody Sequencing">Human/Humanized Antibody Sequencing</a></li><li class="navi-menu-li-4"><a href="/De-Novo-Biosimilar-monoclonal-antibodies-Sequencing-Service.html" title="Biosimilar mAb Sequencing">Biosimilar mAb Sequencing</a></li><li class="navi-menu-li-4"><a href="/de-novo-sdab-sequencing-service.html" title="Single Domain Antibody (SdAb) Sequencing">Single Domain Antibody (SdAb) Sequencing</a></li><li class="navi-menu-li-4"><a href="/De-Novo-Rodent-Antibody-Sequencing-Service.html" title="Rodent Antibody Sequencing">Rodent Antibody Sequencing</a></li><li class="navi-menu-li-4"><a href="/De-Novo-Rabbit-Antibody-Sequencing-Service.html" title="Rabbit Antibody Sequencing">Rabbit Antibody Sequencing</a></li><li class="navi-menu-li-4"><a href="/De-Novo-Chicken-IgYs-Sequencing-Service.html" title="Chicken IgY Sequencing">Chicken IgY Sequencing</a></li><li class="navi-menu-li-4"><a href="/De-Novo-TCR-T-cell-Receptor-Sequencing-Service.html" title="T Cell Receptor (TCR) Sequencing">T Cell Receptor (TCR) Sequencing</a></li></ul></li><li class="navi-menu-li-3"><a href="/antibody-sequencing-service.html" title="Hybridoma Sequencing">Hybridoma Sequencing</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/immunologic-analysis-services.html" title="Immunogenicity Analysis">Immunogenicity Analysis</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/SIAT.html" title="Immunogenicity Assessment">Immunogenicity Assessment</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/in-silico-Immunogenicity-Assessment.html" title="In Silico Assessment">In Silico Assessment</a></li><li class="navi-menu-li-4"><a href="/ex-vivo-Immunogenicity-Assessment.html" title="Ex Vivo Assessment">Ex Vivo Assessment</a></li><li class="navi-menu-li-4"><a href="/in-vivo-Immunogenicity-Assessment.html" title="In Vivo Assessment">In Vivo Assessment</a></li><li class="navi-menu-li-4"><a href="/Anti-drug-Antibodies-ADA-Assays.html" title="Anti-Drug Antibodies (ADA) Assay">Anti-Drug Antibodies (ADA) Assay</a></li></ul></li><li class="navi-menu-li-3"><a href="/Magic-Therapeutic-Antibody-Discovery-Service.htm" title="Repertoire Analysis">Repertoire Analysis</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/magic-bcr-repertoire-analysis.html" title="BCR Repertoire Analysis">BCR Repertoire Analysis</a></li><li class="navi-menu-li-4"><a href="/magic-tcr-repertoire-sequencing-service.html" title="TCR Repertoire Analysis">TCR Repertoire Analysis</a></li></ul></li><li class="navi-menu-li-3"><a href="/ecia.html" title="Cellular Analysis">Cellular Analysis</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/hla-tissue-typing.html" title="HLA Tissue Typing">HLA Tissue Typing</a></li><li class="navi-menu-li-4"><a href="/ecia-b-cell-elispot-assay.html" title="B Cell ELISpot">B Cell ELISpot</a></li><li class="navi-menu-li-4"><a href="/ecia-t-cell-elispot-assay.html" title="T Cell ELISpot">T Cell ELISpot</a></li></ul></li><li class="navi-menu-li-3"><a href="/De-immunogenicity-De-immunization.html" title="De-immunization">De-immunization</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/Antibody-Analysis-Services.html" title="Property Analysis">Property Analysis</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/Isothermal-Titration-Calorimetry-ITC-Service.html" title="ITC Assessment">ITC Assessment</a></li><li class="navi-menu-li-3"><a href="/Differential-scanning-calorimetry-DSC-Service.html" title="DSC Assessment">DSC Assessment</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/drug-discovery/therapeutics/antibody-function-assays.htm" title="Functional Analysis">Functional Analysis</a></li></ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> Services Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-1.jpg" srcset="static/images/Solutions-menu-lights-pic-1.webp 1x" width="201" height="131" loading="lazy"><a href="discovery-services.html" class="bannerbutton">Discovery Services</a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-2.jpg" srcset="static/images/Solutions-menu-lights-pic-2.webp 1x" width="201" height="131" loading="lazy"><a href="engineering-services.html" class="bannerbutton"> Engineering Services </a> </li> </ul> </li> </ul> </div> </div> </li> <li> Engineering <div class="secondMenu"> <div class="second-menu-area-box"> <ul style="margin-top:0;">  <li class="col-md-8 col-lg-8 col-sm-8"> <ul class="navi-menu-2 MenuList"><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/Antibody-Engineering-Services.html" title="Antibody Conversion">Antibody Conversion</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/Human-or-Humanized-Antibody-Services.html" title="Humanization (Convert to Human Ab)">Humanization (Convert to Human Ab)</a></li><li class="navi-menu-li-3"><a href="/Antibody-Camelization-Services.html" title="Camelization (Convert to Single Domain Ab)">Camelization (Convert to Single Domain Ab)</a></li><li class="navi-menu-li-3"><a href="/Antibody-Caninization-Service.html" title="Caninization (Convert to Dog Ab)">Caninization (Convert to Dog Ab)</a></li><li class="navi-menu-li-3"><a href="/Simianization-of-Non-monkey-Antibodies.html" title="Simianization (Convert to NHP Ab)">Simianization (Convert to NHP Ab)</a></li><li class="navi-menu-li-3"><a href="/Antibody-Murinization-Service.html" title="Murinization (Convert to Mouse Ab)">Murinization (Convert to Mouse Ab)</a></li><li class="navi-menu-li-3"><a href="/chimeric-IgG-generation.html" title="Chimeric Antibody Conversion">Chimeric Antibody Conversion</a></li><li class="navi-menu-li-3"><a href="/scfv-fab-generation.html" title="ScFv/Fab Conversion">ScFv/Fab Conversion</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/engineering-services.html" title="Property Optimization">Property Optimization</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/antibody-affinity-maturation.html" title="Affinity Maturation">Affinity Maturation</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/sdab-affinity-maturation.html" title="Single Domain Antibody (SdAb) Affinity Maturation">Single Domain Antibody (SdAb) Affinity Maturation</a></li></ul></li><li class="navi-menu-li-3"><a href="/Antibody-Stability-Improvement.html" title="Stability Improvement">Stability Improvement</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/single-domain-antibody-stability-improvement-service.html" title="Single Domain Antibody (SdAb) Stability Improvement">Single Domain Antibody (SdAb) Stability Improvement</a></li></ul></li><li class="navi-menu-li-3"><a href="/scaffold-specificity-optimization-service.html" title="Specificity Optimization">Specificity Optimization</a></li><li class="navi-menu-li-3"><a href="/Custom-Cysteine-Modification-in-Antibody.html" title="Cysteine Modification">Cysteine Modification</a></li><li class="navi-menu-li-3"><a href="/yeast-display-based-t-cell-receptor-engineering-service.html" title="T Cell Receptor Engineering">T Cell Receptor Engineering</a></li><li class="navi-menu-li-3"><a href="/drug-discovery/therapeutics/fc-engineering-service.htm" title="Fc Engineering">Fc Engineering</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/bioconjugation/" title="Labeling/Conjugation">Labeling/Conjugation</a></li></ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> Services Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-1.jpg" srcset="static/images/Solutions-menu-lights-pic-1.webp 1x" width="201" height="131" loading="lazy"><a href="discovery-services.html" class="bannerbutton">Discovery Services</a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-2.jpg" srcset="static/images/Solutions-menu-lights-pic-2.webp 1x" width="201" height="131" loading="lazy"><a href="engineering-services.html" class="bannerbutton"> Engineering Services </a> </li> </ul> </li> </ul> </div> </div> </li> <li> Custom Production & Manufacturing <div class="secondMenu"> <div class="second-menu-area-box"> <ul style="margin-top:0;">  <li class="col-md-8 col-lg-8 col-sm-8"> <ul class="navi-menu-2 MenuList"><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="Custom Production">Custom Production</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="javascript:void(0)" title="Membrane Protein Preparation">Membrane Protein Preparation</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/Custom-GPCR-Production-Service.html" title="GPCR Preparation">GPCR Preparation</a></li><li class="navi-menu-li-4"><a href="/Custom-Ion-Channel-Protein-Production-Service.html" title="Ion Channel Preparation">Ion Channel Preparation</a></li><li class="navi-menu-li-4"><a href="/Membrane-Transport-Proteins.html" title="Transporter Preparation">Transporter Preparation</a></li><li class="navi-menu-li-4"><a href="/Membrane-Protein-Production.html" title="Custom Membrane Protein Production">Custom Membrane Protein Production</a></li><li class="navi-menu-li-4"><a href="/magic-membrane-protein-solubilization-and-stabilization.html" title="Custom Membrane Protein Solubilization and Stabilization">Custom Membrane Protein Solubilization and Stabilization</a></li><li class="navi-menu-li-4"><a href="/magic-membrane-protein-functional-validation.html" title="Custom Membrane Protein QC">Custom Membrane Protein QC</a></li></ul></li><li class="navi-menu-li-3"><a href="/Virus-like-Particles.html" title="Virus Like Particle (VLP) Production">Virus Like Particle (VLP) Production</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/virus-like-particles-vlps-production-in-insect-cell-system.html" title="Insect Cell based VLP Production">Insect Cell based VLP Production</a></li><li class="navi-menu-li-4"><a href="/virus-like-particles-vlps-production-in-mammalian-cell-system.html" title="Mammalian Cell based VLP Production">Mammalian Cell based VLP Production</a></li><li class="navi-menu-li-4"><a href="/virus-like-particles-vlps-production-in-e-coli-system.html" title="E. coli based VLP Production">E. coli based VLP Production</a></li><li class="navi-menu-li-4"><a href="/virus-like-particles-vlps-production-in-yeast-cell-system.html" title="Yeast Cell based VLP Production">Yeast Cell based VLP Production</a></li><li class="navi-menu-li-4"><a href="/virus-like-particles-vlps-production-in-plant-system.html" title="Plant Cell based VLP Production">Plant Cell based VLP Production</a></li></ul></li><li class="navi-menu-li-3"><a href="/Antibody-Production-Services.html" title="Recombinant Antibody Production">Recombinant Antibody Production</a></li><li class="navi-menu-li-3"><a href="/bulk-antibody-production-by-ascites.html" title="Ascites Fluid based Antibody Production">Ascites Fluid based Antibody Production</a></li><li class="navi-menu-li-3"><a href="/Stable-Cell-Line-Services.html" title="Stable Cell Line Construction">Stable Cell Line Construction</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/bio-manufacturing.html" title="Manufacturing">Manufacturing</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/Manufacturability-Assessment.htm" title="Manufacturability Assessment and Optimization">Manufacturability Assessment and Optimization</a><ul class="navi-menu-4 three_menu"><li class="navi-menu-li-4"><a href="/virtual-prediction-of-manufacturability-assessment-and-improvement.html" title="Virtual Prediction">Virtual Prediction</a></li><li class="navi-menu-li-4"><a href="/amino-acid-sequence-and-terminal-sequence-analysis.html" title="Amino Acid & Terminal Sequence Analysis">Amino Acid & Terminal Sequence Analysis</a></li></ul></li></ul></li></ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> Services Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-1.jpg" srcset="static/images/Solutions-menu-lights-pic-1.webp 1x" width="201" height="131" loading="lazy"><a href="discovery-services.html" class="bannerbutton">Discovery Services</a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Solutions-menu-lights-pic-2.jpg" srcset="static/images/Solutions-menu-lights-pic-2.webp 1x" width="201" height="131" loading="lazy"><a href="engineering-services.html" class="bannerbutton"> Engineering Services </a> </li> </ul> </li> </ul> </div> </div> </li> <li> Products <div class="secondMenu"> <div class="second-menu-area-box"> <ul style="margin-top:0;"> <li class="col-md-8 col-lg-8 col-sm-8"> <ul class="navi-menu-2 MenuList"><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/category-premade-phage-display-library-ready-to-use-kits-4.htm" title="Phage Display Library Ready-To-Use Kits">Phage Display Library Ready-To-Use Kits</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/category-premade-yeast-display-library-ready-to-use-kits-6.htm" title="Yeast Display Library Ready-To-Use Kits">Yeast Display Library Ready-To-Use Kits</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/category-recombinant-antibody-products-2.htm" title="Recombinant Antibody Products">Recombinant Antibody Products</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/category-membrane-protein-products-11.htm" title="Membrane Protein Products">Membrane Protein Products</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/category-nativeextract-membrane-protein-products-38.htm" title="Full-Length Membrane Protein (Super Nanodisc)">Full-Length Membrane Protein (Super Nanodisc)</a></li><li class="navi-menu-li-3"><a href="/category-gpcrs-protein-products-20.htm" title="GPCR Protein">GPCR Protein</a></li><li class="navi-menu-li-3"><a href="/category-transporter-protein-products-21.htm" title="Transporter Protein">Transporter Protein</a></li><li class="navi-menu-li-3"><a href="/category-ion-channel-protein-products-22.htm" title="Ion Channel Protein">Ion Channel Protein</a></li><li class="navi-menu-li-3"><a href="/category-car-t-therapy-target-protein-products-23.htm" title="CAR-T Therapy Target Protein">CAR-T Therapy Target Protein</a></li><li class="navi-menu-li-3"><a href="/category-biomarkers-and-cd-protein-products-24.htm" title="Biomarkers and CD Protein">Biomarkers and CD Protein</a></li><li class="navi-menu-li-3"><a href="/category-fc-receptor-protein-products-25.htm" title="Fc Receptor Protein">Fc Receptor Protein</a></li><li class="navi-menu-li-3"><a href="/category-hla-protein-products-26.htm" title="HLA Protein">HLA Protein</a></li><li class="navi-menu-li-3"><a href="/category-cell-free-protein-products-27.htm" title="Cell-Free Protein">Cell-Free Protein</a></li><li class="navi-menu-li-3"><a href="/category-mp-vlps-products-28.htm" title="MP-VLP">MP-VLP</a></li><li class="navi-menu-li-3"><a href="/category-other-membrane-protein-products-29.htm" title="Other Membrane Protein">Other Membrane Protein</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/category-membrane-protein-expression-kits-30.htm" title="Membrane Protein Expression Kits">Membrane Protein Expression Kits</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/category-magic-cell-free-membrane-protein-expression-kits-32.htm" title="Cell-Free Membrane Protein Expression Kits">Cell-Free Membrane Protein Expression Kits</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/category-membrane-protein-solubilization-and-stabilization-reagents-33.htm" title="Membrane Protein Solubilization & Stabilization Reagents">Membrane Protein Solubilization & Stabilization Reagents</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/category-detergents-34.htm" title="Detergent">Detergent</a></li><li class="navi-menu-li-3"><a href="/category-phospholipids-35.htm" title="Phospholipid">Phospholipid</a></li><li class="navi-menu-li-3"><a href="/category-nanodiscs-36.htm" title="Nanodisc">Nanodisc</a></li><li class="navi-menu-li-3"><a href="/category-polymer-37.htm" title="Polymer">Polymer</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/category-membrane-protein-stable-cell-line-products-10.htm" title="Membrane Protein Stable Cell Line Products">Membrane Protein Stable Cell Line Products</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/adc/classify-products-5.htm" title="Antibody-Drug Conjugate (ADC) Products">Antibody-Drug Conjugate (ADC) Products</a></li></ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> Products With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Products-menu-lights-pic-1.jpg" srcset="static/images/Products-menu-lights-pic-1.webp 1x" width="200" height="131" loading="lazy"><a href="Premade-single-domain-antibody-library.html" class="bannerbutton"> sdAb Libraries </a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Products-menu-lights-pic-2.jpg" srcset="static/images/Products-menu-lights-pic-2.webp 1x" width="200" height="131" loading="lazy"><a href="Immunized-Human-Antibody-Library.html" class="bannerbutton"> Immunized hAb Libraries </a> </li> </ul> </li> </ul> </div> </div> </li> <li> Platforms <div class="secondMenu"> <div class="second-menu-area-box"> <ul style="margin-top:0;"> <li class="col-md-8 col-lg-8 col-sm-8"> <ul class="navi-menu-2 MenuList"><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/Phage-Display-Platform.html" title="Phage Display Platform">Phage Display Platform</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/yeast-display-platform.html" title="Yeast Display Platform">Yeast Display Platform</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/Hybridoma-Platform.html" title="Hybridoma Platform">Hybridoma Platform</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/b-cell-sorting-platform.html" title="Single B Cell Sorting Platform">Single B Cell Sorting Platform</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/Membrane-Protein-Platform.html" title="Membrane Protein Platform">Membrane Protein Platform</a></li></ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> Platforms Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Platforms-menu-lights-pic-1.jpg" srcset="static/images/Platforms-menu-lights-pic-1.webp 1x" width="201" height="131" loading="lazy"><a href="b-cell-sorting-platform.html" class="bannerbutton">B-Cell Sorting Platform</a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Platforms-menu-lights-pic-2.jpg" srcset="static/images/Platforms-menu-lights-pic-2.webp 1x" width="201" height="131" loading="lazy"><a href="Phage-Display-Platform.html" class="bannerbutton">Phage Display Platform</a> </li> </ul> </li> </ul> </div> </div> </li> <li> Resources <div class="secondMenu"> <div class="second-menu-area-box">  <ul style="margin-top:0;"> <li class="col-md-8 col-lg-8 col-sm-8"> <ul class="navi-menu-2 MenuList"><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/Peer-reviewed-Publications.html" title="Peer-Reviewed Publications">Peer-Reviewed Publications</a></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/faq.htm" title="Frequently Asked Questions (FAQs)">Frequently Asked Questions (FAQs)</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/antibody-antigen-faq.htm" title="Antibody & Antigen FAQ">Antibody & Antigen FAQ</a></li><li class="navi-menu-li-3"><a href="/surface-technology-faq.html" title="Surface Technology FAQ">Surface Technology FAQ</a></li><li class="navi-menu-li-3"><a href="/antibody-service-faq.html" title="Antibody Service FAQ">Antibody Service FAQ</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="Resource Download">Resource Download</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/conference-resources.html" title="Conference Resources">Conference Resources</a></li><li class="navi-menu-li-3"><a href="/support-documents.html" title="Support Documents">Support Documents</a></li><li class="navi-menu-li-3"><a href="/newsletter.aspx" title="Newsletter">Newsletter</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/knowledge-center.html" title="Knowledge Hub">Knowledge Hub</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/protocol.html" title="Protocol Instances">Protocol Instances</a></li><li class="navi-menu-li-3"><a href="/technology-introductions.html" title="Technology Introductions">Technology Introductions</a></li><li class="navi-menu-li-3"><a href="/background-knowledges.html" title="Background Knowledges">Background Knowledges</a></li><li class="navi-menu-li-3"><a href="/antibody-overviews.html" title="Antibody Overviews">Antibody Overviews</a></li><li class="navi-menu-li-3"><a href="/membrane-protein-types-introduction.html" title="Membrane Protein Overviews">Membrane Protein Overviews</a></li><li class="navi-menu-li-3"><a href="/scaffold-overviews.html" title="Scaffold Overviews">Scaffold Overviews</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="javascript:void(0)" title="Host Spot Insight">Host Spot Insight</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/literature.html" title="Literature Review">Literature Review</a></li><li class="navi-menu-li-3"><a href="/hot-topics.html" title="Hot Topics">Hot Topics</a></li></ul></li><li class="navi-menu-li-2 col-md-4 col-lg-4 col-sm-4"><a href="/podcast.html" title="Podcast">Podcast</a><ul class="navi-menu-3 three_menu"><li class="navi-menu-li-3"><a href="/surface-display-technology-podcasts.html" title="Surface Display Technology">Surface Display Technology</a></li><li class="navi-menu-li-3"><a href="/recombinant-antibody.html" title="Recombinant Antibody">Recombinant Antibody</a></li><li class="navi-menu-li-3"><a href="/therapeutic-antibody.html" title="Therapeutic Antibody">Therapeutic Antibody</a></li><li class="navi-menu-li-3"><a href="/de-novo-antibody-sequencing.html" title="De Novo Antibody Sequencing">De Novo Antibody Sequencing</a></li><li class="navi-menu-li-3"><a href="/membrane-protein.html" title="Membrane Protein">Membrane Protein</a></li></ul></li></ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> Resources With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Resources-menu-lights-pic-1.jpg" srcset="static/images/Resources-menu-lights-pic-1.webp 1x" width="201" height="131" loading="lazy"><a href="Peer-reviewed-Publications.html" class="bannerbutton">Peer-Reviewed Publications</a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Resources-menu-lights-pic-2.jpg" srcset="static/images/Resources-menu-lights-pic-2.webp 1x" width="201" height="131" loading="lazy"><a href="support-documents.html" class="bannerbutton">Support Documents</a> </li> </ul> </li> </ul> </div> </div> </li> <li> Company <div class="secondMenu"> <div class="second-menu-area-box"> <ul style="margin-top:0;">  <li class="col-md-8 col-lg-8 col-sm-8"> <ul class=" MenuList"> <li class="col-md-4 col-lg-4 col-sm-4"><a href="aboutus.html" rel="nofollow">About Creative Biolabs</a> <ul class="navi-menu-2 three_menu"> <li class="navi-menu-li-2"><a href="/Licensing-and-Collaboration.html" title="Licensing and Collaboration">Licensing and Collaboration</a></li> </ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"><a href="contactus.html" rel="nofollow">Contact Us</a></li> <li class="col-md-4 col-lg-4 col-sm-4"><a href="Distributors.html" rel="nofollow">Distributors</a></li> <li class="col-md-4 col-lg-4 col-sm-4"><a href="feedback.aspx">Reviews & Endorsements</a></li> <li class="col-md-4 col-lg-4 col-sm-4"><a href="/career/career.aspx" rel="nofollow">Careers</a> </li> <li class="col-md-4 col-lg-4 col-sm-4"><a href="https://events.creative-biolabs.com" rel="nofollow">Events</a></li> <li class="col-md-4 col-lg-4 col-sm-4"><a href="scholarship-program.html">Scholarship Program</a></li> <li class="col-md-4 col-lg-4 col-sm-4"><a href="creative-biolabs-corporate-social-responsibility.html">Corporate Social Responsibility</a></li> </ul> </li> <li class="col-md-4 col-lg-4 col-sm-4"> About Us Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.  Highlights <ul class="HighlightsArea"> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Abouts-menu-lights-pic-1.jpg" srcset="static/images/Abouts-menu-lights-pic-1.webp 1x" width="200" height="131" loading="lazy"><a href="aboutus.html" class="bannerbutton"> About CBL </a> </li> <li class="col-md-6 col-lg-6 col-sm-6"> <img src="static/images/Abouts-menu-lights-pic-2.jpg" srcset="static/images/Abouts-menu-lights-pic-2.webp 1x" width="200" height="131" loading="lazy"><a href="contactus.html" class="bannerbutton"> Contact Us </a> </li> </ul> </li> </ul> </div> </div> </li> </ul> <script> window.addEventListener('load',function(){ var arr = ['/drug-discovery/therapeutics/','/bioconjugation/','/adc/']; $('.mennav ul li a').each(function(){ var $this = $(this); var href = $this.attr("href").toLocaleLowerCase(); $.each(arr, function(index, value) { if (href && href.startsWith(value)) { $this.attr('target', '_blank'); } }); }); }); </script> </div> <div class="top-search search-group"> <div class="col-md-5 col-sm-6"> <label class="radio-inline"><input type="radio" name="search" class="rdo_productsearch" value="product" data-type="product" placeholder="Please input cat#, product name, abbr, or keywords."> Product</label> <label class="radio-inline"><input type="radio" name="search" class="rdo_servicesearch" value="service" data-type="service" placeholder="Please input your keywords."> Service</label> <label class="radio-inline"><input type="radio" name="search" class="rdo_googlesearch" value="google" data-type="google" placeholder="Please input your keywords." checked="checked"> Keyword</label> </div> <div class="col-md-7 col-sm-6 search-div"> <input id="keys" name="keys" placeholder="Please input your keywords." class="search-input"> <div class="selectItems"></div> </div> </div> </div> <div class="searchShow"> <div class="searchtopbg"></div> Close <div class="addsearch search-group"></div> </div> <div class="banner_inpage services_bg_2"> <div class="auto-container small_content-width about_container"> <ul class="bread-crumb clearfix"> <li><a href="/">Home</a></li> <li><a href="javascrpt:void(0)">Resources</a></li> <li>Peer-Reviewed Publications</li> </ul> "Creative Biolabs is committed to providing highly customized comprehensive solutions with the best quality to advance our global clients’ projects." </div> </div> <script> window.addEventListener('load', function () { if (($('.bread-crumb li:last-child').text()) == "Peer-Reviewed Publications") { $(".banner_inpage").addClass("peer-reviewed-publications_bg").removeClass("services_bg_2"); } if ($(window).hasClass('bread-crumb')) { if ($(".bread-crumb").html().indexOf("RESOURCE") > -1) { $(".pronote").hide(); } if ($(".bread-crumb").html().indexOf("Careers") > -1) { $(".pronote").hide(); } } }); </script> <div class="small_content-width services-container"> <div class="col-md-9"> <div class="inpage_section_title"> <h1>Peer-Reviewed Publications</h1> </div> <a name="pubtop"></a> <div class="peer-content"> With an unrelenting drive on bio-scientific research and industry, Creative Biolabs is executing on our strategy to bring comprehensive services and products to our clients. We are devoted to accommodating the properties of your project and offering the most valuable solutions to maximize your success. Since 2007, Creative Biolabs has developed high-quality antibody discovery, development, engineering, production, and manufacturing services, as well as other reagents and custom services to worldwide numerous clients of the bio-scientific research and industry. Our expert scientists are dedicated to providing cutting-edge and innovative products and services to support the unique demands and maximizing the probability of success when developing antibodies and other biologics. A long list of articles has been published in peer-reviewed journals and a lot of patents have been approved or in process which cited products or services from Creative Biolabs. This document filed some selected patents and articles to provide an overview about how we can be involved in your academic or industrial project. For your convenience, we have grouped these patents & articles into the following categories: <a href="Peer-Reviewed-Publications.html#_SECTION_1:_Antibody">SECTION 1: Antibody Discovery and Development Services</a> <a href="Peer-Reviewed-Publications.html#_SECTION_2:_Antibody">SECTION 2: Antibody Analysis Services</a> <a href="Peer-Reviewed-Publications.html#_SECTION_3:_Single">SECTION 3: Single Domain Antibody Services and Products</a> <a href="Peer-Reviewed-Publications.html#_SECTION_4:_Antibody-Related">SECTION 4: Antibody-Related Therapeutic Reagent Services and Products</a> <a href="Peer-Reviewed-Publications.html#_SECTION_5:_Phage">SECTION 5: Phage Display Services and Products</a> <a href="Peer-Reviewed-Publications.html#_SECTION_6:_Stable">SECTION 6: Stable Cell Line Services and Products</a> <a href="Peer-Reviewed-Publications.html#_SECTION_7:_Two-Hybrid">SECTION 7: Two-Hybrid Services</a> <a href="Peer-Reviewed-Publications.html#_SECTION_8:_Recombinant">SECTION 8: Recombinant Production Services and Products</a> <a href="Peer-Reviewed-Publications.html#_SECTION_9:_Other">SECTION 9: Other Services and Products</a> <a name="_SECTION_1:_Antibody"></a> SECTION 1: Antibody Discovery and Development Services <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> With over ten years’ extensive experience, Creative Biolabs has blossomed into a service leader in the field of antibody development. We offer comprehensive services with the aim of maximizing the success of your antibody development project. <ul class="ullist disc"> <li> Roy U, Sokolowska I, Woods A G, et al. Structural investigation of tumor differentiation factor[J]. Biotechnology and applied biochemistry, 2012, 59(6): 445-450. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23586953" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described anti-TDF antibodies were generated by Creative Biolabs by using synthesized TDF peptide P1 (TDF-P1) conjugated to KLH as an immunogen. The correct sequence of TDF-P1 was confirmed by MS and the specificity of the antibody was confirmed by pre-incubation of anti-TDF antibodies with its peptide antigen in an inhibition assay. <ul class="ullist disc"> <li> Li Y, Lu Z, Huang Y, et al. F(ab’)2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice[J]. Clinical Immunology, 2016, 173: 50-56.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27455858" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated mouse monoclonal antibodies against modified LDL and generated F(ab’)2 fragments from the monoclonal antibodies. <ul class="ullist disc"> <li> Khan S N, Sok D, Tran K, et al. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry[J]. Journal of virology, 2018, 92(18): e00384-18.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29976677" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs generated eight trispecific design variations of 10E8Fab-PGT121fv-PGDM1400fv. <ul class="ullist disc"> <li> Antony S, Jiang G, Wu Y, et al. Nadph oxidase 5 (nox5)-induced reactive oxygen signaling modulates normoxic Hif-1α and p27Kip1 expression in malignant melanoma and other human tumors[J]. Molecular carcinogenesis, 2017, 56(12): 2643-2662.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28762556" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs developed human anti-NOX5 antibody. <ul class="ullist disc"> <li> Park M A, Kumar A, Jung H S, et al. Activation of the Arterial Program Drives Development of Definitive Hemogenic Endothelium with Lymphoid Potential[J]. Cell reports, 2018, 23(8): 2467-2481.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29791856" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Slukvin, Igor I., Mi Ae Park, and Akhilesh Kumar. "Induction of arterial-type of hemogenic endothelium (ahe) and enhancement of t cell production from pscs through overexpression of ets factors or modulating mapk/erk signalling pathways." US20180142207A1. May 24, 2018.<a href="https://www.google.com/patents/US20180142207A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These paper and patent mentioned Creative Biolabs generated DLL4 blocking antibody used for blocking Notch signaling. <ul class="ullist disc"> <li> Fouladi S, Masjedi M, Ghasemi R, et al. The In Vitro Impact of Glycyrrhizic Acid on CD4+ T Lymphocytes through OX40 Receptor in the Patients with Allergic Rhinitis[J]. Inflammation, 2018, 41(5): 1690-1701.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30003405" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated anti-OX40 agonist mAb. <ul class="ullist disc"> <li> LeBlanc M E, Wang W, Chen X, et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy[J]. Journal of Experimental Medicine, 2017, 214(4): 1029-1047.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28330905" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described anti-Scg3 mAb (clone ML49.3; mouse IgG1) was raised against the full-length human Scg3 (Sino Biological) by Creative Biolabs through a subcontract service and purified from serum-free hybridoma-conditioned medium using protein G Columns. <ul class="ullist disc"> <li> Tenkerian C, Krishnamoorthy J, Mounir Z, et al. mTORC2 balances Akt activation and eIF2alpha serine 51 phosphorylation to promote survival under stress[J]. Molecular Cancer Research, 2015: molcanres. 0184.2015.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26130148" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabsgenerated rabbit antiserum for mouse PERK phosphorylated at T779 by immunizing animals against chemically synthesized phosphor-peptide of mouse PERK conjugated with KLH. <ul class="ullist disc"> <li> Wu Y, Lu J, Antony S, et al. Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-γ and lipopolysaccharide in human pancreatic cancer cell lines[J]. The Journal of Immunology, 2013: 1201725.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23296709" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned mouse anti-human Duox mAb was developed by Creative Biolabs. <ul class="ullist disc"> <li> Borges S, Döppler H, Perez E A, et al. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis[J]. Breast Cancer Research, 2013, 15(2): R66.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23971832" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the mouse monoclonal antibody specific for PKD1 was raised by Creative Biolabs against a 21-amino acid peptide in the N-terminal of human PKD1, which is not present in PKD2 and PKD3. <ul class="ullist disc"> <li> Jia L, Yang J, Hao X, et al. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target[J]. Clinical cancer research, 2010: 1078-0432. CCR-09-1592.<a href="http://www.ncbi.nlm.nih.gov/pubmed/20103673" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described a SAG mAb used for immunostaining analysis was provided by Creative Biolabs. The SAG mAb is raised against purified human SAG RING domain (AA44-113) fused with glutathione S-transferase. <ul class="ullist disc"> <li> Tanese K, Grimm E A, Ekmekcioglu S. The role of melanoma tumor‐derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10[J]. International journal of cancer, 2012, 131(4): 891-901.<a href="http://www.ncbi.nlm.nih.gov/pubmed/21953496" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described a mouse anti-iNOS monoclonal antibody was created by Creative Biolabs, and the anti-iNOS mAb was used to analysis the CXCL10 and CXCL9 expression by immunocytochemistry. <ul class="ullist disc"> <li> Juhasz A, Markel S, Gaur S, et al. NADPH oxidase 1 supports proliferation of colon cancer cells by modulating reactive oxygen species-dependent signal transduction[J]. Journal of Biological Chemistry, 2017: jbc. M116. 768283.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28330872" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described anti-human NOX1 monoclonal antibody (NOX1-Hyb-Clone-22) was developed by Creative Biolabs. <ul class="ullist disc"> <li> Mcallister, Janette M., Jerome F. Strauss, and Neil D. Christensen. "Compositions and Methods for Prophylaxis and/or Therapy of Disorders that Correlate with DENND1A Variant 2." US20170253648A1. Sep 07, 2017.<a href="https://www.google.com/patents/US20170253648A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs developed functional humanized mAb specific to DENND1A.V2 by screening the premade <a href="/premade-human-and-mouse-antibody-libraries.html">Human Single Chain Antibody Library HuScL-2</a>. <ul class="ullist disc"> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” CA2876904 A1. Dec 27. 2013<a href="https://www.google.com/patents/CA2876904A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.“ CN104661677 A. May 27. 2015<a href="https://www.google.com/patents/CN104661677A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” EP2863948 A2. Apr 29. 2015<a href="https://www.google.com/patents/EP2863948A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.“ US9127053 B2. Sep 8. 2015<a href="https://www.google.com/patents/US9127053" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” US20140010810 A1. Jan 9. 2014<a href="https://www.google.com/patents/US20140010810" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” WO2013192550 A2. Dec 27. 2013<a href="https://www.google.com/patents/WO2013192550A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> West, James William, et al. "Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof." US9688748B2. Jun 27, 2017.<a href="https://www.google.com/patents/US9688748B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> West, James William, et al. "Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof." JP2015521625A. Jul 30, 2015.<a href="https://www.google.com/patents/JP2015521625A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> West, James William, et al. "Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof." KR20150037857A. Apr 08, 2015.<a href="https://www.google.com/patents/KR20150037857A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents described Creative Biolabs developed human scFvs against the extracellular domain (ECD) of human Jagged 1 by screening the premade fully Human Single Chain Antibody Library. <ul class="ullist disc"> <li> Nancy E. Stagliano, et al. "Modified Antibody Compositions, Methods of Making and Using Thereof." US20140024810 A1. Jan 23, 2014<a href="https://www.google.com/patents/US20140024810" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al “Modified Antibody Compositions, Methods of Making and Using Thereof.” US20130309230 A1. Nov 21, 2013<a href="https://www.google.com/patents/US20130309230" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al “Modified antibody compositions, methods of making and using thereof.” US8563269 B2. Oct 22, 201<a href="https://www.google.com/patents/US8563269B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al "Modified antibody compositions, methods of making and using thereof." US8513390 B2. Aug 20, 2013<a href="https://www.google.com/patents/US8513390" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al "Modified antibody compositions, methods of making and using thereof." CN102482347 A. May 30, 2012<a href="https://www.google.com/patents/CN102482347A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al. "Modified antibody compositions, methods of making and using thereof." EP2385955 A2. Nov 16, 2011<a href="https://www.google.com/patents/EP2385955A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al. "Modified antibody compositions, methods of making and using thereof." US20100189651 A1. Jul 29, 2010<a href="https://www.google.com/patents/US20100189651" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al. "Modified antibody compositions, methods of making and using thereof."CA2749339 A1. Jul 15, 2010<a href="https://www.google.com/patents/CA2749339A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs discovered anti-human CTLA4 scFv through phage display technology. <ul class="ullist disc"> <li> Antony S, Wu Y, Hewitt S M, et al. Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody[J]. Free Radical Biology and Medicine, 2013, 65: 497-508.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23851018"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated the antigen human Nox5, and develop monoclonal anti-Nox5 antibody through mice immunization and <a href="/custom-antibody-development.html">hybridoma technique</a>. <ul class="ullist disc"> <li> Wang X, Wang S, Lu Y, et al. FAM20C plays an essential role in the formation of murine teeth[J]. Journal of Biological Chemistry, 2012, 287(43): 35934-35942.<a href="http://www.ncbi.nlm.nih.gov/pubmed/22936805" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the detailed procedures of FAM20C monoclonal antibodies production supplied by Creative Biolabs, including immunization, clone screening through hybridoma platform, evaluation through IHC and Western immunoblotting analyses. <ul class="ullist disc"> <li> Jani P H, Gibson M P, Liu C, et al. Transgenic expression of Dspp partially rescued the long bone defects of Dmp1-null mice[J]. Matrix Biology, 2016, 52: 95-112.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26686820" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated full-length human recombinant FGF23 through <a href="/baculovirus-insect-cell-expression-systems.html">baculovirus expression system</a> and developed specific monoclonal antibody through <a href="/omni-hybridomatm-platform.html">Omni-Hybridoma™ technology</a>. <ul class="ullist disc"> <li> Parra G I, Abente E J, Sandoval-Jaime C, et al. Multiple antigenic sites are involved in blocking the interaction of GII. 4 norovirus capsid with ABH histo-blood group antigens[J]. Journal of virology, 2012: JVI. 06729-11.<a href="http://www.ncbi.nlm.nih.gov/pubmed/22532688" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated anti-VLPs mAb through hybridoma technique. <ul class="ullist disc"> <li> Wu Y, Antony S, Juhasz A, et al. Upregulation and sustained activation of STAT1 are essential for interferon-gamma (IFN-gamma)-induced dual oxidase-2 (DUOX2) and dual oxidase A2 (DUOXA2) expression in human pancreatic cancer cell lines[J]. Journal of Biological Chemistry, 2011: jbc. M110. 191031.<a href="http://www.ncbi.nlm.nih.gov/pubmed/21321110"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs developed mouse anti-human Duox2 monoclonal antibody S-40 by using hybridoma technique. <ul class="ullist disc"> <li> Wu Y, Meitzler J L, Antony S, et al. Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A[J]. Oncotarget, 2016, 7(42): 68412.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27637085" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described anti-human DUOX antibody, which reacts with both DUOX1 and DUOX2, was developed by Creative Biolabs using hybridoma technique. <ul class="ullist disc"> <li> Nicola Mason, Daniel J. Powell Jr., Mohammed Kazim PANJWANI, Jenessa SMITH. Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor. WO2017011316A1. Jan 19. 2017<a href="https://www.google.com/patents/WO2017011316A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs generated canine antibodies against selected antigen. <ul class="ullist disc"> <li> Frederick C. S. WANG, Mark H. FOGG. “Neutralizing antibody for Epstein-Barr virus associated disease.” WO2013130565A1. Sep 6, 2013<a href="https://www.google.com/patents/WO2013130565A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Frederick C. S. WANG, Mark H. FOGG. “Neutralizing antibody for Epstein-Barr virus associated disease.” US9376485B2. Jun 28, 2016<a href="https://www.google.com/patents/US9376485B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Frederick C. S. WANG, Mark H. FOGG. “Neutralizing antibody for Epstein-Barr virus associated disease.” US20150064174A1. Mar 5, 2015<a href="https://www.google.com/patents/US20150064174A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs has the capacity to design and generate <a href="/Human-or-Humanized-Antibody-Services.html">fully humanized antibody</a>. <ul class="ullist disc"> <li> Daniel E.H, et al. “Anti-pd-1 antibodies and their uses.” US20180148513A1. May 31, 2018.<a href="https://www.google.com/patents/US20180148513A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Daniel E.H, et al. “Anti-pd-1 antibodies and their uses.” US9914783B1. Mar 13, 2018.<a href="https://patents.google.com/patent/US9914783B1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Harding, Fiona A. "Anti-ox40 antibodies and their uses." WO2018112346A1. Jun 21, 2018.<a href="https://www.google.com/patents/WO2018112346A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Harding, Fiona A. "Anti-ox40 antibodies and their uses." US20180171023A1. Jun 21, 2018.<a href="https://www.google.com/patents/US20180171023A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Harding, Fiona A. "Anti-ox40 antibodies and their uses." US20180194855A1. Jul 12, 2018.<a href="https://www.google.com/patents/US20180194855A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs can discover fully human antibodies against a selected antigen by using transgenic mice and phage display technology. <ul class="ullist disc"> <li> Klaus Andreas RAUE and Eric M. Tam. “Bispecific 4-1bb agonist molecules.” WO2018187215A1. Oct 11, 2018.<a href="https://www.google.com/patents/WO2018187215A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs can generate human antibodies through phage display technology. <ul class="ullist disc"> <li> Roh J, Byun S J, Seo Y, et al. Generation of a chickenized catalytic anti-nucleic acid antibody by complementarity-determining region grafting[J]. Molecular immunology, 2015, 63(2): 513-520.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25458312" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs can reshape non-human antibody into other non-human antibodies such as <a href="/antibody-caninization-service.html">caninization</a> and <a href="/Antibody-Camelization-Services.html">camelization</a>. <ul class="ullist disc"> <li> Braendli-Baiocco A, Festag M, Dumong Erichsen K, et al. From the cover: The minipig is a suitable Non-Rodent model in the safety assessment of single stranded oligonucleotides[J]. Toxicological Sciences, 2017, 157(1): 112-128.<a href="https://www.ncbi.nlm.nih.gov/pubmed/28123102" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated anti-SSO pAb2 rabbit polyclonal antibody. <ul class="ullist disc"> <li> Woods A G, Sokolowska I, Deinhardt K, et al. Identification of tumor differentiation factor (TDF) in select CNS neurons[J]. Brain Structure and Function, 2014, 219(4): 1333-1342.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23681168" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated two rabbit polyclonal anti-TDF antibodies: anti-TDF-P1 antibody (anti-TDF-P1-Ab) and anti-TDF-P1P2P3 antibody (anti-TDF-P1-Ab). <ul class="ullist disc"> <li> Sokolowska I, Woods A G, Gawinowicz M A, et al. Identification of potential tumor differentiation factor (TDF) receptor from steroid-responsive and steroid-resistant breast cancer cells[J]. Journal of Biological Chemistry, 2012, 287(3): 1719-1733.<a href="http://www.ncbi.nlm.nih.gov/pubmed/22130669" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs synthesized TDF-P1 peptide as immunogen and generated rabbit polyclonal TDF-P1 antibody. <ul class="ullist disc"> <li> Morimoto J, Sarkar M, Kenrick S, et al. Dextran as a generally applicable multivalent scaffold for improving immunoglobulin-binding affinities of peptide and peptidomimetic ligands[J]. Bioconjugate chemistry, 2014, 25(8): 1479-1491.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25073654" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated anti-ADP3 chicken IgY by immunizing chicken with ADP3. <ul class="ullist disc"> <li> Doran T M, Kodadek T. A liquid array platform for the multiplexed analysis of synthetic molecule-protein interactions[J]. ACS chemical biology, 2013, 9(2): 339-346.<a href="http://www.ncbi.nlm.nih.gov/pubmed/24245981" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Thomas Kodadek, Todd DORAN. “Liquid array platform for multiplexed analysis of molecule-protein interactions.” WO2014138028A1. Sep 12, 2014<a href="https://www.google.com/patents/WO2014138028A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These paper and patent mentioned Creative Biolabs generated a stock solution containing 14 μM IgY from chicken immunized with ADP3. <ul class="ullist disc"> <li> Wanczyk H, Barker T, Rood D, et al. Cloning and characterization of a hybridoma secreting a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-specific monoclonal antibody and recombinant F(ab)[J]. Toxins, 2013, 5(3): 568-589.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23518474" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs characterized a hybridoma with proper amplification and sequencing strategy. An F(ab) antibody was then designed and produced with similar binding ability to that of the parent hybridoma. <ul class="ullist disc"> <li> Peng H, Brimijoin S, Hrabovska A, et al. Comparison of 5 monoclonal antibodies for immunopurification of human butyrylcholinesterase on Dynabeads: KD values, binding pairs, and amino acid sequences[J]. Chemico-biological interactions, 2015, 240: 336-345.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26343001" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs amplified and sequenced the complete cDNA sequence of a hybridoma. A corresponding recombinant antibody was then produced with consistent binding ability to that of the parent hybridoma. <ul class="ullist disc"> <li> Ma L, Gu K, Zhang C, et al. Generation and characterization of a human sdAb against VEGFR-2[J]. Acta Pharmacologica Sinica, 2016, 37(6): 857.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27108602" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described human anti-VEGFR2 D3 sdAbs were selected from Creative Biolabs’ premade Human Single Domain Antibody Library. <ul class="ullist disc"> <li> Suratt, Benjamin T. "Suppression of leptin action for treatment of pulmonary infections." U.S. Patent No. 20,150,329,635. Nov 19, 2015. <a href="http://www.patentsencyclopedia.com/app/20150329635" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned leptin antagonist single domain antibody can be custom-made from Creative Biolabs. <ul class="ullist disc"> <li> Kim D Y, Hussack G, Kandalaft H, et al. Mutational approaches to improve the biophysical properties of human single-domain antibodies[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2014, 1844(11): 1983-2001.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25065345" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs is a company focused on the development of human single domain antibodies as therapeutics and affinity reagents. <ul class="ullist disc"> <li> De Yoreo J. Research methods in biomineralization science[M]. Elsevier, 2013.<a href="https://books.google.com/books/about/Research_Methods_in_Biomineralization_Sc.html?id=VMuRrPeOoIsC" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This book described Creative Biolabs has advanced phage display platform, which can offer comprehensive custom services, such as the generation of antibody, peptide, cDNA library, and the corresponding library screening processes. <ul class="ullist disc"> <li> Shuen, Amy. "Nanoparticles for Delivery of Agents to Glioblastoma Tumors." US20170326252A1. Nov 16, 2017.<a href="https://www.google.com/patents/US20170326252A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs can offer custom service to generate single chain antibodies. <ul class="ullist disc"> <li> Maragos C M, Li L, Chen D. Production and characterization of a single chain variable fragment (scFv) against the mycotoxin deoxynivalenol[J]. Food and agricultural immunology, 2012, 23(1): 51-67.<a href="http://www.tandfonline.com/doi/full/10.1080/09540105.2011.598921"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs offered a comprehensive hybridoma cell line culture service and generate the scFv and Fab format of the hybridoma clone. <ul class="ullist disc"> <li> Kelliher M T, Jacks R D, Piraino M S, et al. The effect of sugar removal on the structure of the Fc region of an IgG antibody as observed with single molecule Förster Resonance Energy Transfer[J]. Molecular immunology, 2014, 60(2): 103-108.<a href="http://www.ncbi.nlm.nih.gov/pubmed/24813166" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Piraino M S, Kelliher M T, Aburas J, et al. Single molecule Förster resonance energy transfer studies of the effect of EndoS deglycosylation on the structure of IgG[J]. Immunology letters, 2015, 167(1): 29-33.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26112419" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These papers described Creative Biolabs produced a mutated IgG from HEK 293E cells by replacing Ser 258 in each heavy chain with cysteine mutation. <ul class="ullist disc"> <li> Liewen, Heike, et al. "Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX)." Targeted oncology 14.5 (2019): 577-590.<a href="https://link.springer.com/article/10.1007/s11523-019-00667-z" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs was commissioned to synthesize peptide SSRSVDLQTRIMELEGRVRR (rG2p) and the c-terminal biotinylated version rG2p-PEG-Biotin, as well as provide human scFV libraries screening services in four rounds against these peptides. <ul class="ullist disc"> <li> Lin, Qing, et al. "HIMF (hypoxia-induced mitogenic factor) signaling mediates the HMGB1 (high mobility group box 1)-dependent endothelial and smooth muscle cell crosstalk in pulmonary hypertension." Arteriosclerosis, thrombosis, and vascular biology 39.12 (2019): 2505-2519.<a href="https://ahajournals.org/doi/10.1161/ATVBAHA.119.312907" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-HIMF therapeutic antibody was developed in cooperation with Creative Biolabs. <a name="_SECTION_2:_Antibody"></a> SECTION 2: Antibody Analysis Services <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> Creative Biolabs has developed the proprietary <a href="/next-generation-antibody-sequencing.html">Database Assisted Shotgun Sequencing (DASS)</a> technology, which is based on the next generation antibody sequencing platform. Monoclonal antibodies in multivalent forms and hybridoma clones can be sequenced with 100% coverage and 100% accuracy. <ul class="ullist disc"> <li> Shen, Hongqiang, and Shu, Qiang. “Antibody for resisting human CD79a extracellular terminal protein, coding gene and application.” CN107488230A. Dec 19, 2017.<a href="https://www.google.com/patents/CN107488230A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs provided de novo sequencing with high accuracy through the proprietary Database Assisted Shotgun Sequencing (DASS) technology. <ul class="ullist disc"> <li> Wanczyk H, Barker T, Rood D, et al. Cloning and characterization of a hybridoma secreting a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-specific monoclonal antibody and recombinant F(ab)[J]. Toxins, 2013, 5(3): 568-589.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23518474" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs characterized a hybridoma with proper amplification and sequencing strategy. An F(ab) antibody was then designed and produced with similar binding ability to that of the parent hybridoma. <ul class="ullist disc"> <li> Peng H, Brimijoin S, Hrabovska A, et al. Comparison of 5 monoclonal antibodies for immunopurification of human butyrylcholinesterase on Dynabeads: KD values, binding pairs, and amino acid sequences[J]. Chemico-biological interactions, 2015, 240: 336-345.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26343001" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs amplified and sequenced the complete cDNA sequence of a hybridoma. A corresponding recombinant antibody was then produced with consistent binding ability to that of the parent hybridoma. <ul class="ullist disc"> <li> Hammerberg, Bruce, Sitka Eguiluz-Hernandez, and Thierry Olivry. "Treatment of allergic diseases with chimeric protein." US20180230236A1. Aug 16, 2018.<a href="https://www.google.com/patents/US20180230236A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hammerberg, Bruce, Sitka Eguiluz-Hernandez, and Thierry Olivry. "Treatment of allergic diseases with chimeric protein." WO2018089335A1. May 17, 2018.<a href="https://www.google.com/patents/WO2018089335A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hammerberg B, Eguiluz-Hernandez S. Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in four dogs[J]. Veterinary dermatology, 2017, 28(1): 52-e13.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27426720"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents and paper mentioned Creative Biolabs successfully sequenced the heavy and light chain variable regions of a mouse monoclonal antibody. <ul class="ullist disc"> <li> Gernot Stuhler. “Dual antigen-induced bipartite functional complementation.” CA2861003A1. Jul 18. 2013<a href="https://www.google.com/patents/CA2861003A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gernot Stuhler. “Dual antigen-induced bipartite functional complementation.” EP2802607A2. Nov 19. 2014<a href="https://www.google.com/patents/EP2802607A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gernot Stuhler. “Dual antigen-induced bipartite functional complementation.” US20150079093A1. Mar 19. 2015<a href="https://www.google.com/patents/US20150079093" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gernot Stuhler. “Dual antigen-induced bipartite functional complementation.” WO2013104804A2. Jul 18. 2013<a href="https://www.google.com/patents/WO2013104804A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gernot Stuhler. “Dual antigen-induced bipartite functional complementation.” WO2013104804A3. Nov 21, 2013<a href="https://www.google.com/patents/WO2013104804A3" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gernot Stuhler. “Dual antigen-induced bipartite functional complementation.” CN 104159923A. Nov 19, 2014<a href="https://www.google.com/patents/CN104159923A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Bao X, Pachikara N D, Oey C B, et al. Non-coding nucleotides and amino acids near the active site regulate peptide deformylase expression and inhibitor susceptibility in Chlamydia trachomatis[J]. Microbiology, 2011, 157(9): 2569-2581.<a href="http://www.ncbi.nlm.nih.gov/pubmed/21719536" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents and paper described Creative Biolabs performed full genome sequencing including library preparation, Solexa cluster generation, and single-end-read sequencing. <ul class="ullist disc"> <li> Gao Y C, Jia Y, Xiao D Q, et al. Development and characterization of monoclonal antibody against human IL-37b[J]. Cytotechnology, 2017, 69(2): 217-227.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28214995" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs performed the variable region sequence of an antibody by RT-PCR. <ul class="ullist disc"> <li> Gonen, Ayelet, et al. "A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma." Journal of lipid research 60.2 (2019): 436-445.<a href="http://www.jlr.org/content/60/2/436.short" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned AG23 heavy and light chains were sequenced by Creative Biolabs. <a name="_SECTION_3:_Single"></a> SECTION 3: Single Domain Antibody Services and Products <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> Creative Biolabs is specialized in developing <a href="sdAb-Single-Domain-Antibody.html">novel single domain antibodies (sdAbs)</a> against your targets of interest. We can discover sdAb through either immune or premade libraries and develop the candidates through humanization and affinity maturation. <ul class="ullist disc"> <li> Ma L, Gu K, Zhang C, et al. Generation and characterization of a human sdAb against VEGFR-2[J]. Acta Pharmacologica Sinica, 2016, 37(6): 857.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27108602" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described human anti-VEGFR2 D3 sdAbs were selected from Creative Biolabs’ premade Human Single Domain Antibody Library. <ul class="ullist disc"> <li> Suratt, Benjamin T. "Suppression of leptin action for treatment of pulmonary infections." U.S. Patent No. <a name="OLE_LINK6"></a><a name="OLE_LINK5"></a>20,150,329,635. Nov 19, 2015. <a href="http://www.patentsencyclopedia.com/app/20150329635" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned leptin antagonist single domain antibody can be custom-made from Creative Biolabs. <ul class="ullist disc"> <li> Doshi R, Chen B R, Vibat C R T, et al. In vitro sdAb discovery for integral membrane protein targets[J]. Scientific reports, 2014, 4: 6760.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25342225" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned premade Human Single Domain Antibody Library, which based on the camelized human VH3 with elongated and randomized HCDR3, is available at Creative Biolabs. <ul class="ullist disc"> <li> Kim D Y, Hussack G, Kandalaft H, et al. Mutational approaches to improve the biophysical properties of human single-domain antibodies[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2014, 1844(11): 1983-2001.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25065345" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs is a company focused on the development of human single domain antibodies as therapeutics and affinity reagents. <ul class="ullist disc"> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” WO2016065323 A2. Apr 28, 2016.<a href="https://www.google.com/patents/WO2016065323A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against tnfalpha.” US20160115226 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115226" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against kras.” US20160115244 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115244" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” US20160115247 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115247" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda Singh. “Single domain antibodies directed against intracellular antigens.” US20170327598A1. Nov 16, 2017.<a href="https://www.google.com/patents/US20170327598A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against stat3.” US20160115248 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115248" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” WO2016065323 A3. Jun 16, 2016.<a href="https://www.google.com/patents/WO2016065323A3" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” US20170267784A1. Sep 21, 2017.<a href="https://www.google.com/patents/US20170267784A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned anti-KRAS sdAb is available at Creative Biolabs. <ul class="ullist disc"> <li> <a href="https://patents.google.com/?inventor=Jerry+Clifford">Jerry Clifford</a>, <a href="https://patents.google.com/?inventor=Ben+Thompson">Ben Thompson</a>. <a name="OLE_LINK19"></a><a name="OLE_LINK18"></a>A method of determining the abundance of a target molecule in a sample. WO2017103210 A1. Jun 22, 2017<a href="https://www.google.com/patents/WO2017103210A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned a series of single domain antibodies can be purchased from Creative Biolabs. <ul class="ullist disc"> <li> Chatterjee S, Daenthanasanmak A, Chakraborty P, et al. CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response[J]. Cell metabolism, 2018, 27(1): 85-100. e8.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29129787" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-CD38 VHH single domain antibody is available at Creative Biolabs. <ul class="ullist disc"> <li> <a href="https://patents.google.com/?inventor=Paul+C.+Lee">Paul C. Lee</a>. “Nanoparticle probes and methods of making and use thereof.” US20170269095A1. Sep 21, 2017.<a href="https://www.google.com/patents/US20170269095A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> <a href="https://patents.google.com/?inventor=Paul+C.+Lee">Paul C. Lee</a>. “Nanoparticle probes and methods of making and use thereof.” US20180000972A1. Jan 04, 2018.<a href="https://www.google.com/patents/US20180000972A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned anti-ICAM1 VHH antibody biotinylated at the C-terminus was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Singh, Sunanda, et al. "Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3." Breast cancer: basic and clinical research 12 (2018): 1178223417750858. <a href="https://journals.sagepub.com/doi/full/10.1177/1178223417750858" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs provided VHHs against STAT3, as well as the second PCR product from STAT3 VHH gene and pCDisplay-3M phagemid. <ul class="ullist disc"> <li> Mashalidis, Ellene H., et al. "Chemical logic of MraY inhibition by antibacterial nucleoside natural products." Nature communications 10.1 (2019): 1-12. <a href="https://www.nature.com/articles/s41467-019-10957-9" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned MraYAA sdAbs were raised by phage display technology using immunized llama as a repertoire source in partnership with Creative Biolabs. <a name="_SECTION_4:_Antibody-Related"></a> SECTION 4: Antibody-Related Therapeutic Reagent Services and Products <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> Creative Biolabs has established powerful platforms to discover and develop antibody-related therapeutic reagents, which including but not limited to Chimeric Antigen Receptor (CAR), Bispecific Antibody (bsAb), and Antibody-Drug Conjugates (ADC). We can accommodate the specific properties of your project and provide flexible integrated solutions. <ul class="ullist disc"> <li> Biswas M, Brusko T M, Herzog R W. Generation of FVIII-Specific Tregs Expressing a Chimeric Antigen Receptor (CAR) to Suppress Inhibitor Development in Hemophilia a Mice[J]. 2017.<a href="http://www.bloodjournal.org/content/130/Suppl_1/176?utm_source=TrendMD%26utm_medium=cpc%26utm_campaign=Blood_TrendMD_0%26sso-checked=true" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs developed a 2nd generation CAR construct expressing CD28 and CD3ζ signaling molecules and packaged in a retroviral system (pMys-IRES-eGFP). <ul class="ullist disc"> <li> Novik, Shai, and Dror Mevorach. "Combination immune therapy and cytokine control therapy for cancer treatment." <a name="OLE_LINK10"></a><a name="OLE_LINK9"></a>US20180094244A1. Apr 05, 2018.<a href="https://www.google.com/patents/US20180094244A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Novik, Shai, and Dror Mevorach. "Combination immune therapy and cytokine control therapy for cancer treatment." US20170360836A1. Dec 21, 2017.<a href="https://www.google.com/patents/US20170360836A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs offered comprehensive CAR-T cell services including custom construction, CAR production, as well as premade CAR constructs stock. <ul class="ullist disc"> <li> Zhang F, Stephan S B, Ene C I, et al. Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T cell therapy in solid malignancies[J]. Cancer research, 2018: canres. 0306.2018.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29760047" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the anti-EGFRvIII-28z CAR was custom-designed by Creative Biolabs. <ul class="ullist disc"> <li> Jeon B N, Kim H R, Chung Y S, et al. Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1[J]. Oncoimmunology, 2018, 7(12): e1500674.<a href="https://www.ncbi.nlm.nih.gov/pubmed/30524895" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs provided CD19 targeted CAR viral plasmid to help the researchers establish the human CD19 targeted CAR-T cells. <ul class="ullist disc"> <li> Mcnagny, Kelly Marshall, et al. "Anti-podocalyxin antibodies and methods of using the same." US20180296673A1. Oct 18, 2018.<a href="https://www.google.com/patents/US20180296673A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned services for generating CAR-NK cells are commercially available at Creative Biolabs. <ul class="ullist disc"> <li> Sedykh S E, Prinz V V, Buneva V N, et al. Bispecific antibodies: design, therapy, perspectives[J]. Drug design, development and therapy, 2018, 12: 195.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29403265" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned <a href="/bsab/dutamab-generation-service.htm">DutaMab technology</a> (using three CDRs in each antigen-binding site to bind one target and the other three CDRs to bind the second target, thus forming two paratopes) is available at Creative Biolabs. <ul class="ullist disc"> <li> Hernández P, Gorrochategui J, Primo D, et al. Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry[J]. SLAS TECHNOLOGY: Translating Life Sciences Innovation, 2017, 22(3): 325-337.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28340541" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs generated anti-CD3×CD123 bispecific antibody. <ul class="ullist disc"> <li> Babcook, John, Mads Daugaard, and E. L. Ali. "Compositions and methods for the treatment of platinum-drug resistant cancer." US20180193473A1. Jul 12, 2018.<a href="https://www.google.com/patents/US20180193473A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs can provide drug-linkers suitable for reaction with a selected targeting moiety, such as linker-toxins comprising MMAE or MMAF SA. <ul class="ullist disc"> <li> Ng, Gordon Yiu Kon, Leonard G. Presta, and Thomas SPRETER VON KREUDENSTEIN. "Drug-conjugated bi-specific antigen-binding constructs." US20180193477A1. Jul 12, 2018.<a href="https://www.google.com/patents/US20180193477A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gordon Yiu King NG, Leonard G. Presta, VON KREUDENSTEIN, Thomas SPRETER. Drug-conjugated bi-specific antigen-binding constructs. WO2017008169A1. Jan 19. 2017<a href="https://www.google.com/patents/WO2017008169A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs can provide several pre-formed drug-linkers suitable for reaction with a selected antigen binding construct, for example, linker-toxins comprising DM1, DM4, MMAE, MMAF or Duocarmycin SA. <ul class="ullist disc"> <li> Govindan, Serengulam V., et al. "RS7 antibodies." US9833511B2. Dec 05, 2017.<a href="https://www.google.com/patents/US9833511B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Govindan, Serengulam V., et al. "RS7 antibodies." US9849176B2. Dec 26, 2017.<a href="https://www.google.com/patents/US9849176B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Govindan, Serengulam V., et al. "RS7 antibodies." US9745380B2. Aug 29, 2017.<a href="https://www.google.com/patents/US9745380B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned that Anti-Trop-2 (clone 7E6)-AcLys-VC-PABC-MMAD" datasheet was available from Creative Biolabs. <ul class="ullist disc"> <li> Kim D Y, Hussack G, Kandalaft H, et al. Mutational approaches to improve the biophysical properties of human single-domain antibodies[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2014, 1844(11): 1983-2001.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25065345" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs is a company focused on the development of human single domain antibodies as therapeutics and affinity reagents. <ul class="ullist disc"> <li> Schiffmann L M, Fritsch M, Gebauer F, et al. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer[J]. British journal of cancer, 2018: 1.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30377339" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-VEGF therapeutic antibody B20-4.1.1 used in syngeneic subcutaneous tumor model was purchased from Creative Biolabs. <a name="_SECTION_5:_Phage"></a> SECTION 5: Phage Display Services and Products <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> With the advanced phage display platform, Creative Biolabs is devoted to discovering and developing novel antibodies through comprehensive library construction and screening services. We can also provide high-quality human antibody libraries to assist your project. <ul class="ullist disc"> <li> Gabriel M. Gutierrez, et al. “PD-1 Peptide Inhibitors.” US20180185474A1. Jul 05, 2018.<a href="https://www.google.com/patents/US20180185474A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gabriel M. Gutierrez, et al. “PD-1 Peptide Inhibitors.” US20180071385A1. Mar 15, 2018.<a href="https://www.google.com/patents/US20180071385A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Gabriel M. Gutierrez, et al. “PD-1 Peptide Inhibitors.” US20180200328A1. Jul 19, 2018.<a href="https://www.google.com/patents/US20180200328A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents described Creative Biolabs identified strong peptide binders against soluble recombinant human PD-1 receptor by screening premade TriCo-20™ and TriCo-16™ Phage Display Peptide Libraries. <ul class="ullist disc"> <li> Vuong Trieu, Xiping Liu, and Neil Desai. "Sparc binding antibodies and uses thereof." EP 2563393 A1. Mar 6, 2013<a href="https://www.google.com/patents/EP2563393A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Vuong Trieu, Xiping Liu, and Neil Desai. "Sparc binding antibodies and uses thereof." EP2563393 B1. Jun 8, 2016<a href="https://www.google.com/patents/EP2563393B1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Vuong Trieu, Xiping Liu, and Neil Desai. "Sparc binding antibodies and uses thereof." US 9096660B2 US 13/643,609. Aug 4,2015<a href="https://www.google.com/patents/US9096660" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Vuong Trieu, Xiping Liu, and Neil Desai. "Sparc binding antibodies and uses thereof." WO 2011137114 A1. Nov 3, 2011<a href="https://www.google.com/patents/WO2011137114A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Vuong Trieu, Xiping Liu, Neil Desai. “Peripheral blood SPARC antibodies and uses thereof.” CN103221062 A Jul 24, 2013<a href="https://www.google.com/patents/CN103221062A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Vuong Trieu, Xiping Liu, Neil Desai. “Peripheral blood sparc antibodies and uses thereof.” WO2011153431 A2. Dec 8, 2011<a href="https://www.google.com/patents/WO2011153431A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Vuong Trieu, Xiping Liu, Neil Desai. “Peripheral blood sparc binding antibodies and uses thereof.” CA 2801184 A1. Dec 8, 2011<a href="https://www.google.com/patents/CA2801184A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Vuong Trieu, Xiping Liu, Neil Desai. “Peripheral blood sparc binding antibodies and uses thereof.” US20120052007 A1. Mar 1, 2012<a href="https://patents.google.com/patent/US20120052007A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents described fully human anti-human SPARC antibodies was isolated from Creative Biolabs’ premade Human Fab Antibody Library. <ul class="ullist disc"> <li> John T. Unger, Rolf Hilfiker. “Conformational epitope initiated signal amplification.” US20120040337 A1. Feb 16, 2012<a href="https://www.google.com/patents/US20120040337" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> John T. Unger, Rolf Hilfiker. “Conformational epitope initiated signal amplification.” WO 2010118300 A1. Oct 14, 2010<a href="https://www.google.com/patents/WO2010118300A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents described mouse anti-C1Q binding site and mouse anti-FcgR1 binding site Fabs are isolated from a phage display library which was offered by Creative Biolabs. <ul class="ullist disc"> <li> De Yoreo J. Research methods in biomineralization science[M]. Elsevier, 2013.<a href="https://books.google.com/books/about/Research_Methods_in_Biomineralization_Sc.html?id=VMuRrPeOoIsC" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This book described Creative Biolabs has advanced phage display platform, which can offer comprehensive custom services, such as the generation of antibody, peptide, cDNA library, and the corresponding library screening processes. <ul class="ullist disc"> <li> Hingorani D V, Whitney M A, Friedman B, et al. Nerve-targeted probes for fluorescence-guided intraoperative imaging[J]. Theranostics, 2018, 8(15): 4226.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30128049" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs provides a custom-synthesized M13 phage library expressing 16 random amino acids on the N-terminus of gIII. <ul class="ullist disc"> <li> Soto C M, Ratna B R. Virus hybrids as nanomaterials for biotechnology[J]. Current opinion in biotechnology, 2010, 21(4): 426-438.<a href="http://www.ncbi.nlm.nih.gov/pubmed/20688511" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs can offer <a href="/phage-display-library-construction.html">custom phage display library construction services</a>. <ul class="ullist disc"> <li> Torres L, Almazán C, Ayllón N, et al. Functional genomics of the horn fly, Haematobia irritans (Linnaeus, 1758)[J]. BMC genomics, 2011, 12(1): 105.<a href="http://www.ncbi.nlm.nih.gov/pubmed/21310032" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs generated <a href="/cdna-library-construction-service.html">custom cDNA library</a> for the analysis of expressed sequence tags (ESTs) in adult female horn flies. <ul class="ullist disc"> <li> Fukunaga K, Taki M. Practical tips for construction of custom peptide libraries and affinity selection by using commercially available phage display cloning systems[J]. Journal of nucleic acids, 2012, 2012.<a href="http://www.ncbi.nlm.nih.gov/pubmed/22991651" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs can offer <a href="/phage-display-library-screening.html">custom library screening services</a> for either commercial premade library or custom-constructed library. <ul class="ullist disc"> <li> Alessandra Franco. "Glycopeptides and methods of making and using them." WO 2009108807 A1. Sep 3, 2009<a href="https://www.google.com/patents/WO2009108807A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Alessandra Franco. "Glycopeptides and methods of making and using them." EP2250189 A1. Nov 17, 2012<a href="https://www.google.com/patents/EP2250189A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Alessandra Franco. "Glycopeptides and methods of making and using them." US20110045046 A1. Feb 24, 2011<a href="https://www.google.com/patents/US20110045046"> </a> </li> <li> Alessandra Franco. "Glycopeptides and methods of making and using them." CA 2716622 A1. Sep 3, 2009<a href="https://www.google.com/patents/CA2716622A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Alessandra Franco. "Glycopeptides and methods of making and using them." US 9156906 B2. Oct 13, 2015<a href="https://www.google.com/patents/US9156906" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned <a href="/premade-phage-display-peptide-libraries.html">premade synthetic peptide phage display libraries</a> are available at Creative Biolabs. <ul class="ullist disc"> <li> Welch, Brett D., et al. "Compositions and methods related to inhibition of respiratory syncytial virus entry." US20180280520A1. Oct 04, 2018.<a href="https://www.google.com/patents/US20180280520A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Brett D. Welch Michael S. Kay Debra Muir ECKERT Rena MCKINNON Michael Thomas JACOBSEN. Compositions and methods related to inhibition of respiratory syncytial virus entry. WO2017040350 A1. Mar. 9.2017<a href="https://www.google.com/patents/WO2017040350A1"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned two linear peptide phage display libraries are commercially available at Creative Biolabs. <ul class="ullist disc"> <li> Tay M Y F, Lee C C, Vasudevan S G, et al. Identification of dengue-specific human antibody fragments using phage display[M]//Dengue. Humana Press, New York, NY, 2014: 161-173.<a href="http://www.ncbi.nlm.nih.gov/pubmed/24696337" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned premade Human Naïve Fab Library is available at Creative Biolabs. <ul class="ullist disc"> <li> Zhao A, Tohidkia M R, Siegel D L, et al. Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy[J]. Critical reviews in biotechnology, 2016, 36(2): 276-289.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25394539" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs provides a series of premade Human Single Chain Antibody Libraries. <ul class="ullist disc"> <li> Omidfar K, Daneshpour M. Advances in phage display technology for drug discovery[J]. Expert opinion on drug discovery, 2015, 10(6): 651-669.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25910798" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned that the most widely used commercial phage display peptide libraries are provided by Creative Biolabs, which contains 107-10 variants. <ul class="ullist disc"> <li> Melidoni A N, Dyson M R, McCafferty J. Selection of antibodies interfering with cell surface receptor signaling using embryonic stem cell differentiation[M]//Embryonic Stem Cell Protocols. Humana Press, New York, NY, 2015: 111-132.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26036698" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned premade phage display antibody libraries are available at Creative Biolabs. <ul class="ullist disc"> <li> Curtis S, Lederer F L, Dunbar W S, et al. Identification of mineral‐binding peptides that discriminate between chalcopyrite and enargite[J]. Biotechnology and bioengineering, 2017, 114(5): 998-1005.<a href="https://www.ncbi.nlm.nih.gov/pubmed/27861731" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Braun R, Bachmann S, Schönberger N, et al. Peptides as Biosorbents–Promising tools for Resource Recovery[J]. Research in microbiology, 2018.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29928986" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These papers mentioned F88-Cys4 12-mer peptide library is available at Creative Biolabs. <ul class="ullist disc"> <li> Jones M L, Mahler S M, Kumble S. Selection of Antibodies to Transiently Expressed Membrane Proteins Using Phage Display[M]//Antibody Engineering. Humana Press, New York, NY, 2018: 179-195.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30196498" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned various premade phage display antibody libraries are commercially available at Creative Biolabs. <ul class="ullist disc"> <li> Kurabi A, Schaerer D, Chang L, et al. Optimisation of peptides that actively cross the tympanic membrane by random amino acid extension: a phage display study[J]. Journal of drug targeting, 2018, 26(2): 127-134.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28658990" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned two phage libraries used in this research were provided by Creative Biolabs. <ul class="ullist disc"> <li> Bi G, Wu L, Huang P, et al. Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown[J]. The FASEB Journal, 2018: fj. 201701059R.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29452569" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Human Single Chain Antibody Library HuScL-2 is available at Creative Biolabs. <ul class="ullist disc"> <li> Doshi R, McGrath A P, Piñeros M, et al. Functional characterization and discovery of modulators of SbMATE, the agronomically important aluminium tolerance transporter from Sorghum bicolor[J]. Scientific reports, 2017, 7(1): 17996.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29269936" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned a naïve camelid single-domain library was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Xu, Ting, et al. "Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)." WO2017020802A1. Feb 09, 2017.<a href="https://www.google.com/patents/WO2017020802A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Xu, Ting, et al. "Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)." KR20180033582A. Apr 03, 2018.<a href="https://www.google.com/patents/KR20180033582A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Xu, Ting, et al. "Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)." EP3330290A1. Jun 06, 2018.<a href="https://www.google.com/patents/EP3330290A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Xu, Ting, et al. "Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)." US20180291103A1. Oct 11, 2018.<a href="https://www.google.com/patents/US20180291103A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Xu, Ting, et al. "Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)." JP2018531039A. Oct 25, 2018.<a href="https://www.google.com/patents/JP2018531039A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Ting Xu, Yanrong DONG, Pilin WANG, Ting Chen. “Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof.” WO2017020801 A1. Feb 9, 2017.<a href="https://www.google.com/patents/WO2017020801A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Xu, Ting, et al. "SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST PROGRAMMED DEATH-LIGAND (PDL1)." US20180327494A1. Nov 15, 2018.<a href="https://www.google.com/patents/US20180327494A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned that the single domain antibody was cloned into phage display vector pCDisplay-3 which was provided by Creative Biolabs. <ul class="ullist disc"> <li> Mcallister, Janette M., Jerome F. Strauss, and Neil D. Christensen. "Compositions and Methods for Prophylaxis and/or Therapy of Disorders that Correlate with DENND1A Variant 2." US20170253648A1. Sep 07, 2017.<a href="https://www.google.com/patents/US20170253648A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs developed functional humanized mAb specific to DENND1A.V2 by screening the premade <a href="/premade-human-and-mouse-antibody-libraries.html">Human Single Chain Antibody Library HuScL-2</a>. <ul class="ullist disc"> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” CA2876904 A1. Dec 27. 2013<a href="https://www.google.com/patents/CA2876904A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.“ CN104661677 A. May 27. 2015<a href="https://www.google.com/patents/CN104661677A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” EP2863948 A2. Apr 29. 2015<a href="https://www.google.com/patents/EP2863948A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.“ US9127053 B2. Sep 8. 2015<a href="https://www.google.com/patents/US9127053" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” US20140010810 A1. Jan 9. 2014<a href="https://www.google.com/patents/US20140010810" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> James William WEST, Jason Gary SAGERT, Paul H. Bessette, Henry Bernard LOWMAN, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary MENENDEZ. “Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.” WO2013192550 A2. Dec 27. 2013<a href="https://www.google.com/patents/WO2013192550A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> West, James William, et al. "Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof." US9688748B2. Jun 27, 2017.<a href="https://www.google.com/patents/US9688748B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> West, James William, et al. "Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof." JP2015521625A. Jul 30, 2015.<a href="https://www.google.com/patents/JP2015521625A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> West, James William, et al. "Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof." KR20150037857A. Apr 08, 2015.<a href="https://www.google.com/patents/KR20150037857A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents described Creative Biolabs developed human scFvs against the extracellular domain (ECD) of human Jagged 1 by screening the premade fully Human Single Chain Antibody Library. <ul class="ullist disc"> <li> Nancy E. Stagliano, et al. "Modified Antibody Compositions, Methods of Making and Using Thereof." US20140024810 A1. Jan 23, 2014<a href="https://www.google.com/patents/US20140024810" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al “Modified Antibody Compositions, Methods of Making and Using Thereof.” US20130309230 A1. Nov 21, 2013<a href="https://www.google.com/patents/US20130309230" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al “Modified antibody compositions, methods of making and using thereof.” US8563269 B2. Oct 22, 201<a href="https://www.google.com/patents/US8563269B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al "Modified antibody compositions, methods of making and using thereof." US8513390 B2. Aug 20, 2013<a href="https://www.google.com/patents/US8513390" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al "Modified antibody compositions, methods of making and using thereof." CN102482347 A. May 30, 2012<a href="https://www.google.com/patents/CN102482347A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al. "Modified antibody compositions, methods of making and using thereof." EP2385955 A2. Nov 16, 2011<a href="https://www.google.com/patents/EP2385955A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al. "Modified antibody compositions, methods of making and using thereof." US20100189651 A1. Jul 29, 2010<a href="https://www.google.com/patents/US20100189651" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Nancy E. Stagliano, et al. "Modified antibody compositions, methods of making and using thereof."CA2749339 A1. Jul 15, 2010<a href="https://www.google.com/patents/CA2749339A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs discovered anti-human CTLA4 scFv through phage display technology. <ul class="ullist disc"> <li> Daniel E.H, et al. “Anti-pd-1 antibodies and their uses.” US20180148513A1. May 31, 2018.<a href="https://www.google.com/patents/US20180148513A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Daniel E.H, et al. “Anti-pd-1 antibodies and their uses.” US9914783B1. Mar 13, 2018.<a href="https://patents.google.com/patent/US9914783B1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Harding, Fiona A. "Anti-ox40 antibodies and their uses." WO2018112346A1. Jun 21, 2018.<a href="https://www.google.com/patents/WO2018112346A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Harding, Fiona A. "Anti-ox40 antibodies and their uses." US20180171023A1. Jun 21, 2018.<a href="https://www.google.com/patents/US20180171023A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Harding, Fiona A. "Anti-ox40 antibodies and their uses." US20180194855A1. Jul 12, 2018.<a href="https://www.google.com/patents/US20180194855A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs can discover fully human antibodies against a selected antigen by using transgenic mice and phage display technology. <ul class="ullist disc"> <li> Klaus Andreas RAUE and Eric M. Tam. “Bispecific 4-1bb agonist molecules.” WO2018187215A1. Oct 11, 2018.<a href="https://www.google.com/patents/WO2018187215A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs can generate human antibodies through phage display technology. <ul class="ullist disc"> <li> Ma L, Gu K, Zhang C, et al. Generation and characterization of a human sdAb against VEGFR-2[J]. Acta Pharmacologica Sinica, 2016, 37(6): 857.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27108602" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described human anti-VEGFR2 D3 sdAbs were selected from Creative Biolabs’ premade Human Single Domain Antibody Library. <ul class="ullist disc"> <li> Doshi R, Chen B R, Vibat C R T, et al. In vitro sdAb discovery for integral membrane protein targets[J]. Scientific reports, 2014, 4: 6760.<a href="http://www.ncbi.nlm.nih.gov/pubmed/25342225" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned premade Human Single Domain Antibody Library, which based on the camelized human VH3 with elongated and randomized HCDR3, is available at Creative Biolabs. <ul class="ullist disc"> <li> Singh S, Murillo G, Chen D, et al. Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3[J]. Breast cancer: basic and clinical research, 2018, 12: 1178223417750858.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29434474" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned pCDis-play-3M phagemid and STAT3 protein used in immunoprecipitation were purchased from Creative Biolabs <ul class="ullist disc"> <li> Lederer, F. L., et al. "Identification of peptides as alternative recycling tools via phage surface display–How biology supports Geosciences." Minerals Engineering 132 (2019): 245-250.<a href="https://www.sciencedirect.com/science/article/abs/pii/S0892687518305491" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs constructed f88.4/Cys6 16-mer peptide library through phage display technology, which was used for the identification of LaPO4:Ce3+, Tb3+-binding peptides. <ul class="ullist disc"> <li> Zhu, Wenli, et al. "Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD." Neurology-Neuroimmunology Neuroinflammation 6.3 (2019): e561.<a href="https://nn.neurology.org/content/6/3/e561.abstract" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs provided the semisynthetic scFv phage library for Escherichia coli TG1 bacteria which was cultured and infected with M13KO7 helper phage. <a name="_SECTION_6:_Stable"></a> SECTION 6: Stable Cell Line Services and Products <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> Creative Biolabs can provide a range of <a href="/stable-cell-line-services.html">custom stable cell lines</a>through our proprietary gene screening and amplification system. The cell lines are grown in suspension and produce high yields of recombinant proteins in chemically defined medium. These manufacturing cell lines have been accepted by CMO's and manufacturers worldwide to produce <a href="/cgmp-manufacturing.html">cGMP</a> material. <ul class="ullist disc"> <li> Hanneke Lucia Dorothea Maria WILLEMEN, and Niels EIJKELKAMP. “Inhibitors of lysine methyltransferase for treatment of pain.” WO2018190713A1. Oct 18, 2018.<a href="https://www.google.com/patents/WO2018190713A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned the HEK293 cells including HEK293T, HEK293E, HEK-293F, and HEK-293FT are commercially available at Creative Biolabs. <ul class="ullist disc"> <li> Huang G, Docampo R. The mitochondrial Ca2+ uniporter complex (MCUC) of Trypanosoma brucei is a hetero-oligomer that contains novel subunits essential for Ca2+ uptake[J]. MBio, 2018, 9(5): e01700-18.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30228243" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the Saccharomyces cerevisiae NMY51 MYTH reporter strain [MATa his3Δ200 trp1-901 leu2-3,112 ade2 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-lacZ ade2::(lexAop)8-ADE2 GAL4] was obtained from Creative Biolabs. <ul class="ullist disc"> <li> Niazi S K. Biosimilars and Interchangeable Biologics: Tactical Elements[M]. CRC Press, 2016.<a href="https://www.taylorfrancis.com/books/9781498743501" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This book described Creative Biolabs is specialized in providing customized stable cell line service and analytical support. <ul class="ullist disc"> <li> Iz S G, Inevi M A, Metiner P S, et al. A biodesign approach to obtain high yields of biosimilars by anti-apoptotic cell engineering: A case study to increase the production yield of anti-TNF alpha producing recombinant CHO cells[J]. Applied biochemistry and biotechnology, 2018, 184(1): 303-322.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28685239" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned humanized anti-TNFα mAb, suspension culture, and serum-free medium adapted stable CHO cell line were obtained from Creative Biolabs. <ul class="ullist disc"> <li> Zhao, Tieqiang, Aiilyan Houng, and Guy L. Reed. "Termination of Bleeding by a Specific, Anti‐catalytic Antibody to Plasmin." Journal of Thrombosis and Haemostasis (2019).<a href="https://onlinelibrary.wiley.com/doi/10.1111/jth.14522" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the expression of a humanized chimeric version of Pi in HEK293 cells by transient cell transfection was obtained from Creative Biolabs. <ul class="ullist disc"> <li> Bulutoglu, Beyza, et al. "Rapid maturation of the hepatic cell line Huh7 via CDK inhibition for PXR dependent CYP450 metabolism and induction." Scientific reports 9.1 (2019): 1-9.<a href="https://www.nature.com/articles/s41598-019-52174-w" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the human hepatoma cell line (Huh7) was obtained from Creative Biolabs. <a name="_SECTION_7:_Two-Hybrid"></a> SECTION 7: Two-Hybrid Services <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> Creative Biolabs is able to provide <a href="custom-yeast-two-hybrid-screening-service.html">two-hybrid screening</a> services for the investigation of protein-protein or protein-peptide interaction in vivo. We can provide many types of two hybrid services, such as yeast two-hybrid (Y2H), mammalian two-hybrid (M2H), bacterial two-hybrid (B2H), and reverse yeast two-hybrid (rYTH) to meet your specific demands. <ul class="ullist disc"> <li> Horgan C P, Hanscom S R, Kelly E E, et al. Tumor susceptibility gene 101 (TSG101) is a novel binding-partner for the class II Rab11-FIPs[J]. PLoS One, 2012, 7(2): e32030.<a href="http://www.ncbi.nlm.nih.gov/pubmed/22348143" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs performed yeast two-hybrid screening with full-length FIP4 as bait against an adult human brain cDNA library. <ul class="ullist disc"> <li> Brown C, Szpryngiel S, Kuang G, et al. Structural and functional characterization of the microtubule interacting and trafficking domains of two oomycete chitin synthases[J]. The FEBS journal, 2016, 283(16): 3072-3088.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27363606" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs established a cDNA library for yeast two-hybrid screening. <ul class="ullist disc"> <li> Chen L X, Morales-Alcala C C, Riobo-Del Galdo N A. Autophagic Flux Is Regulated by Interaction Between the C-terminal Domain of PATCHED1 and ATG101[J]. Molecular Cancer Research, 2018: molcanres. 0597.2017.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29453315" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the yeast two-hybrid screening was carried out by Creative Biolabs using the Matchmaker Gold Yeast Two-Hybrid System. <ul class="ullist disc"> <li> Batissoco A, Salazar-Silva R, Oiticica J, et al. A Cell Junctional Protein Network Associated with Connexin-26[J]. International journal of molecular sciences, 2018, 19(9): 2535.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30150563" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the X-gal assay supported for yeast two-hybrid assay was offered by Creative Biolabs. <ul class="ullist disc"> <li> KARAKAYA, BURCU. ESTABLISHMENT OF CELL LINES WITH INDUCIBLE EXPRESSION OF shRNA FOR AN ESTROGEN RESPONSIVE GENE. Diss. MIDDLE EAST TECHNICAL UNIVERSITY, 2018.<a href="http://etd.lib.metu.edu.tr/upload/12622161/index.pdf" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned that yeast two-hybrid screening was carried out by Creative BioLabs to determine possible interacting partners of CXXC5. <a name="_SECTION_8:_Recombinant"></a> SECTION 8: Recombinant Production Services and Products <a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> Creative Biolabs offers extensive expertise across four expression systems for recombinant antibody/protein production, which include bacterial, yeast, baculovirus-insect cell, and mammalian cell. We do also provide comprehensive <a href="/Membrane-Protein-Production.html">membrane protein production services</a>. <ul class="ullist disc"> <li> Shuen, Amy. "Nanoparticles for Delivery of Agents to Glioblastoma Tumors." US20170326252A1. Nov 16, 2017.<a href="https://www.google.com/patents/US20170326252A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned Creative Biolabs can offer custom service to generate single chain antibodies. <ul class="ullist disc"> <li> Maragos C M, Li L, Chen D. Production and characterization of a single chain variable fragment (scFv) against the mycotoxin deoxynivalenol[J]. Food and agricultural immunology, 2012, 23(1): 51-67.<a href="http://www.tandfonline.com/doi/full/10.1080/09540105.2011.598921"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs offered a comprehensive hybridoma cell line culture service and generate the scFv and Fab format of the hybridoma clone. <ul class="ullist disc"> <li> Timoshevskaya I. Single-Molecule Fluorescence Studies of Glycosylated and Aglycosylated Antibodies[J]. DePaul Discoveries, 2012, 1(1): 11.<a href="https://via.library.depaul.edu/depaul-disc/vol1/iss1/11/" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs found the sequence errors of provided humanized IgG and fixed them to achieve successful antibody production. <ul class="ullist disc"> <li> Guo Z, Liu Y, Cheng M. Resveratrol protects bupivacaine-induced neuro-apoptosis in dorsal root ganglion neurons via activation on tropomyosin receptor kinase A[J]. Biomedicine & Pharmacotherapy, 2018, 103: 1545-1551.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29864941" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the functional TrkA blocking antibody or non-specific IgG antibody were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Kelliher M T, Jacks R D, Piraino M S, et al. The effect of sugar removal on the structure of the Fc region of an IgG antibody as observed with single molecule Förster Resonance Energy Transfer[J]. Molecular immunology, 2014, 60(2): 103-108.<a href="http://www.ncbi.nlm.nih.gov/pubmed/24813166" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Piraino M S, Kelliher M T, Aburas J, et al. Single molecule Förster resonance energy transfer studies of the effect of EndoS deglycosylation on the structure of IgG[J]. Immunology letters, 2015, 167(1): 29-33.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26112419" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These papers described Creative Biolabs produced a mutated IgG from HEK 293E cells by replacing Ser 258 in each heavy chain with cysteine mutation. <ul class="ullist disc"> <li> Ye Liu, et al. “Vaccine compositions containing modified zika virus antigens.” US20170354729A1. Dec 14, 2017.<a href="https://www.google.com/patents/US20170354729A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned two antibodies, C8 and C10, which bind specifically to the dimer epitope bind to protein expressed from BV1944 were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Tacha, David, and Weimin Qi. “Anti-SOX10 antibody systems and methods.” US20160216269A1. Jul 28, 2016.<a href="https://www.google.com/patents/US20160216269A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Tacha, David, and Weimin Qi. "Anti-p40 antibodies systems and methods." WO2014134587A1. Sep 04, 2014.<a href="https://www.google.com/patents/WO2014134587A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Tacha, David, and Weimin Qi. "Anti-p40 antibodies systems and methods." EP2962113A4. Nov 09, 2016.<a href="https://www.google.com/patents/EP2962113A4" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Tacha, David, and Weimin Qi. "Anti-p40 antibodies systems and methods." US20160333085A1. Nov 17, 2016.<a href="https://www.google.com/patents/US20160333085A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Wardell, Seth, and James Bender. "PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY." U.S. Patent Application No. 15/940,901.<a href="http://www.freepatentsonline.com/y2018/0325954.html" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned chimeric IgG construction service and 4-1BB agonist-monoclonal antibody are available at Creative Biolabs. <ul class="ullist disc"> <li> Adrienne M. DORRANCE, Ramiro Garzon. “Recombinant egfl7, egfl7 antibodies, and uses thereof.” WO2018200465A1. Nov 01, 2018.<a href="https://www.google.com/patents/WO2018200465A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned anti-human EGFL7 antibody is available at Creative Biolabs. <ul class="ullist disc"> <li> Poirier, Nicolas, et al. “New uses of anti-sirpg antibodies.” WO2018149938A1. Aug 23, 2018.<a href="https://www.google.com/patents/WO2018149938A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned antibodies binding to SIRPg and SIRPa were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Brenner, Michael, et al. “Targeting gamma-delta t cells in obesity and cachexia.” WO2018201130A1. Nov 01, 2018.<a href="https://www.google.com/patents/WO2018201130A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned anti-IL-33 antibody is available at Creative Biolabs. <ul class="ullist disc"> <li> Harrop, Richard. “Method.” WO2018167486A1. Sep 20, 2018.<a href="https://www.google.com/patents/WO2018167486A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned 5T4 specific antibody is available at Creative Biolabs. <ul class="ullist disc"> <li> <a href="https://patents.google.com/?inventor=Michael+T.+Lotze&scholar">Michael T. Lotze</a>, and Krit RITTHIPICHAI. “Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists.” WO2018129332A1. Jul 12, 2018.<a href="https://www.google.com/patents/WO2018129332A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned the OX40 agonist, 4- IBB agonist, TNFRSF agonist were available at Creative Biolabs. <ul class="ullist disc"> <li> Ekmekcioglu S, Chattopadhyay C, Akar U, et al. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells[J]. Nutrition and cancer, 2011, 63(6): 940-949.<a href="http://www.ncbi.nlm.nih.gov/pubmed/21745040" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned inducible nitric oxide synthase (iNOS) antibody used in IHC was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Clarke E, et al. “Bystander Effects of Antibody Drug Conjugates on the Hematopoietic Compartment.” Society of Toxicology 57th Annual Meeting & ToxExpo 2018, Poster Abstract No.2325.<a href="https://www.reachbio.com/blog/bystander-effects-of-antibody-drug-conjugates-on-the-hematopoietic-compartment" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This blog mentioned Trastuzumab and Trastuzumab-vc-MMAE are available at Creative Biolabs. <ul class="ullist disc"> <li> Chen W, Mack A, Sachok B, et al. Performance of Optimized Wide Pore Superficially Porous Particles for Separation of Proteins and Immunoglobulin G Antibodies[J]. Journal of chromatographic science, 2018, 56(5): 416-424.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29522182" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned humanized recombinant trastuzumab (Herceptin) IgG1 intact was provided by Creative Biolabs. <ul class="ullist disc"> <li> de Oliveira G C, Kanamori K S, Auxiliadora-Martins M, et al. Measuring CD38 Hydrolase and Cyclase Activities: 1,N6-Ethenonicotinamide Adenine Dinucleotide (ε-NAD) and Nicotinamide Guanine Dinucleotide (NGD) Fluorescence-based Methods[J]. Bio-protocol, 2018, 8(14).<a href="http://www.ncbi.nlm.nih.gov/pubmed/30112426" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-CD38 antibody was provided by Creative Biolabs. <ul class="ullist disc"> <li> Gilbert B E, Patel N, Lu H, et al. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge[J]. Vaccine, 2018, 36(52): 8069-8078.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30389195" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned antibody D25 was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Chan B M, Badh A, Berry K A, et al. Flow Cytometry-Based Epitope Binning Using Competitive Binding Profiles for the Characterization of Monoclonal Antibodies against Cellular and Soluble Protein Targets[J]. SLAS DISCOVERY: Advancing Life Sciences R&D, 2018: 2472555218774334.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29783865" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned MF12 antibody L49 for flow cytometry application was provided by Creative Biolabs. <ul class="ullist disc"> <li> Wang Y, Chen J N, Yang L B, et al. Tumor-contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine-Paracrine Loop[J]. Clinical Cancer Research, 2018: clincanres. 2544.2018.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30482778" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned neutralizing antibodies against Frizzled2 were provided by Creative Biolabs. <ul class="ullist disc"> <li> Greil R, Hutterer E, Hartmann T N, et al. Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation[J]. Cell Communication and Signaling, 2017, 15(1): 5.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28100240" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned ADCC enhanced anti-CD274 antibody was provided by Creative Biolabs. <ul class="ullist disc"> <li> Gu X, Wei C, Zhu X, et al. Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β[J]. Experimental and therapeutic medicine, 2018, 16(1): 171-177.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29896237" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-human IL-31RA antibody was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Dukhovny A, Shlomai A, Sklan E H. The antiviral protein Viperin suppresses T7 promoter dependent RNA synthesis-possible implications for its antiviral activity[J]. Scientific reports, 2018, 8(1): 8100.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29802323" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-T7 polymerase antibody was provided by Creative Biolabs. <ul class="ullist disc"> <li> Schiffmann L M, Fritsch M, Gebauer F, et al. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer[J]. British journal of cancer, 2018: 1.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30377339" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-VEGF therapeutic antibody B20-4.1.1 used in syngeneic subcutaneous tumor model was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Nanki K, Toshimitsu K, Takano A, et al. Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis[J]. Cell, 2018, 174(4): 856-869. e17.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30096312" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-human frizzled receptor antibody used in the flow cytometry analysis was provided by Creative Biolabs. <ul class="ullist disc"> <li> Blatt A Z, Saggu G, Cortes C, et al. Factor h c-Terminal Domains are critical for regulation of Platelet/granulocyte aggregate Formation[J]. Frontiers in immunology, 2017, 8: 1586.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29218045" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-C5 antibody was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Tosetti F, Venè R, Camodeca C, et al. Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells[J]. OncoImmunology, 2018, 7(5): e1421889.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29721369" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-CD30 human antibody was provided by Creative Biolabs. <ul class="ullist disc"> <li> Osuna C E, Lim S Y, Kublin J L, et al. Evidence that CD32a does not mark the HIV-1 latent reservoir[J]. Nature, 2018, 561(7723): E20.<a href="http://www.ncbi.nlm.nih.gov/pubmed/30232424" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned antibody CD32b (2B6) was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Kannan, Raghuraman, et al. “Compositions for the treatment of drug-resistant tumors and methods of use thereof.” WO2018183944A1. Oct 01, 2018.<a href="https://www.google.com/patents/WO2018183944A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned a series of anti-AXL antibodies are available at Creative Biolabs. <ul class="ullist disc"> <li> Lobato-Álvarez J A, Roldán M L, López-Murillo T C, et al. The Apical Localization of Na+, K+-ATPase in Cultured Human Retinal Pigment Epithelial Cells Depends on Expression of the β2 Subunit[J]. Frontiers in physiology, 2016, 7: 450.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27774068" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-Na+, K+-ATPase β2 subunit antibody is available at Creative Biolabs. <ul class="ullist disc"> <li> Henry K A, Hussack G, Collins C, et al. Isolation of TGF-β-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing[J]. Protein Engineering, Design and Selection, 2016, 29(10): 439-443.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27613412" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-RSV antibody was provided by Creative Biolabs. <ul class="ullist disc"> <li> Chen W, Jiang K, Mack A, et al. Synthesis and optimization of wide pore superficially porous particles by a one-step coating process for separation of proteins and monoclonal antibodies[J]. Journal of Chromatography A, 2015, 1414: 147-157.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26342871" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned papain digested IgG was provided by Creative Biolabs. <ul class="ullist disc"> <li> Turkson, James. "Drug composition cytotoxic for pancreatic cancer cells." US8685941 B2. Apr, 2014.<a href="https://www.google.com/patents/US8685941" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Turkson, James. "Drug composition cytotoxic for pancreatic cancer cells." EP2370082 A1. Oct 5, 2011.<a href="https://www.google.com/patents/EP2370082A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Turkson, James. "Drug composition cytotoxic for pancreatic cancer cells." WO 2010065444 A1. Jun 10, 2010.<a href="https://www.google.com/patents/WO2010065444A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Turkson, James. "Drug composition cytotoxic for pancreatic cancer cells." CA 2745265 A1. Jun 10, 2010.<a href="https://www.google.com/patents/CA2745265A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned recombinant human EGF (hEGF) is available at Creative Biolabs. <ul class="ullist disc"> <li> Thomas K, Todd D. “Liquid array platform for multiplexed analysis of molcule-protein interactions.” WO 2014138028 A1. Sep 12, 2014.<a href="https://www.google.com/patents/WO2014138028A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned ADP3 is available at Creative Biolabs. <ul class="ullist disc"> <li> Qi, Hong. "Camelid single-domain hcv antibodies and methods of use." U.S. Patent Application No. 15/567,353.<a href="https://www.google.com/patents/US20180292408A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent described the recombinant protein (1-120 amino acid with His tag) purified from Pichia is commercially available at Creative Biolabs. <ul class="ullist disc"> <li> Hetényi A, Németh L, Wéber E, et al. Competitive inhibition of TRPV1–calmodulin interaction by vanilloids[J]. FEBS letters, 2016, 590(16): 2768-2775.<a href="http://www.ncbi.nlm.nih.gov/pubmed/27339229" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned uniformly 13C- and 15N-labelled CaM was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Kim M S, Song H J, Lee S H, et al. Comparative study of various growth factors and cytokines on type I collagen and hyaluronan production in human dermal fibroblasts[J]. Journal of cosmetic dermatology, 2014, 13(1): 44-51.<a href="http://www.ncbi.nlm.nih.gov/pubmed/24641605" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described all human recombinant cytokines used in the study were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Lopez-Rivera E, Jayaraman P, Parikh F, et al. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2[J]. Cancer research, 2014: canres. 0588.2013.<a href="http://www.ncbi.nlm.nih.gov/pubmed/24398473" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned iNOS was supplied by Creative Biolabs. <ul class="ullist disc"> <li> Cheng Y, Cawley N X, Loh Y P. Carboxypeptidase E/NFα1: a new neurotrophic factor against oxidative stress-induced apoptotic cell death mediated by ERK and PI3-K/AKT pathways[J]. PloS one, 2013, 8(8): e71578.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23977080" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the purified recombinant WT mouse CPE was custom generated by Creative Biolabs. <ul class="ullist disc"> <li> Lee C, Hu J, Ralls S, et al. The molecular profiles of neural stem cell niche in the adult subventricular zone[J]. PloS one, 2012, 7(11): e50501.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23209762" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described mouse CPE used in the research was expressed and purified by Creative Biolabs. <ul class="ullist disc"> <li> Jaganathan, Soumya, Peibin Yue, and James Turkson. "Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src."J Pharmacol Exp Ther. 2010 May;333(2):373-81<a href="http://www.ncbi.nlm.nih.gov/pubmed/20100905" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the recombinant human EGF is available at Creative Biolabs. <ul class="ullist disc"> <li> Murthy S R K, Dupart E, Al-Sweel N, et al. Carboxypeptidase E promotes cancer cell survival, but inhibits migration and invasion[J]. Cancer letters, 2013, 341(2): 204-213.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23941827" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described recombinant mouse full-length CPE was expressed in HEK293 cells and purified by Creative Biolabs. <ul class="ullist disc"> <li> Bah G S, Tanya V N, Makepeace B L. Immunotherapy with mutated onchocystatin fails to enhance the efficacy of a sub-lethal oxytetracycline regimen against Onchocerca ochengi[J]. Veterinary parasitology, 2015, 212(1-2): 25-34.<a href="http://www.ncbi.nlm.nih.gov/pubmed/26100152" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs produced the recombinant mutated onchocystatin in Escherichia coli. <ul class="ullist disc"> <li> Ka-Yiu San, Hui Wu. “Intergrated biodiesel process.” US20140335578 A1. Nov 13, 2014.<a href="https://www.google.com/patents/US20140335578" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned YeastXceed™ Technology is available at Creative Biolabs. <ul class="ullist disc"> <li> Ukaegbu-Obi K M. Single cell protein: a resort to global protein challenge and waste management[J]. J Microbiol Microb Technol, 2016, 1(1): 5.<a href="https://www.researchgate.net/profile/Kelechi_Ukaegbu-Obi2/publication/318947586_Citation_Kelechi_M_Ukaegbu-Obi_Single_Cell_Protein_A_Resort_to_Global_Protein_Challenge_and_Waste_Management_Single_Cell_Protein_A_Resort_to_Global_Protein_Challenge_and_Waste_Management/links/598770e00f7e9b6c8537451c/Citation-Kelechi-M-Ukaegbu-Obi-Single-Cell-Protein-A-Resort-to-Global-Protein-Challenge-and-Waste-Management-Single-Cell-Protein-A-Resort-to-Global-Protein-Challenge-and-Waste-Management.pdf" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs has developed Single Protein Production (SPP) TM technology for high-throughput protein production. <ul class="ullist disc"> <li> Morçöl T, Weidner J M, Mehta A, et al. Calcium phosphate particles as pulmonary delivery system for interferon-α in Mice[J]. AAPS PharmSciTech, 2018, 19(1): 395-412.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28752471" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described that recombinant human IFNα-2a (rhIFNα) expressed in E. coli was obtained from Creative Biolabs. <ul class="ullist disc"> <li> Liu D, Ray B, Neavin D R, et al. Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics[J]. Translational psychiatry, 2018, 8(1): 10.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29317604" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the recombinant human DEFB1 protein used for LPS preincubation was provided by Creative Biolabs. <ul class="ullist disc"> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” WO2016065323 A2. Apr 28, 2016.<a href="https://www.google.com/patents/WO2016065323A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against tnfalpha.” US20160115226 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115226" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against kras.” US20160115244 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115244" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” US20160115247 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115247" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda Singh. “Single domain antibodies directed against intracellular antigens.” US20170327598A1. Nov 16, 2017.<a href="https://www.google.com/patents/US20170327598A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against stat3.” US20160115248 A1. Apr 28, 2016.<a href="https://www.google.com/patents/US20160115248" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” WO2016065323 A3. Jun 16, 2016.<a href="https://www.google.com/patents/WO2016065323A3" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Sunanda SINGH. “Single domain antibodies directed against intracellular antigens.” US20170267784A1. Sep 21, 2017.<a href="https://www.google.com/patents/US20170267784A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned anti-KRAS sdAb is available at Creative Biolabs. <ul class="ullist disc"> <li> <a href="https://patents.google.com/?inventor=Jerry+Clifford">Jerry Clifford</a>, <a href="https://patents.google.com/?inventor=Ben+Thompson">Ben Thompson</a>. A method of determining the abundance of a target molecule in a sample. WO2017103210 A1. Jun 22, 2017<a href="https://www.google.com/patents/WO2017103210A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned a series of single domain antibodies can be purchased from Creative Biolabs. <ul class="ullist disc"> <li> Chatterjee S, Daenthanasanmak A, Chakraborty P, et al. CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response[J]. Cell metabolism, 2018, 27(1): 85-100. e8.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29129787" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned anti-CD38 VHH single domain antibody is available at Creative Biolabs. <ul class="ullist disc"> <li> <a href="https://patents.google.com/?inventor=Paul+C.+Lee">Paul C. Lee</a>. “Nanoparticle probes and methods of making and use thereof.” US20170269095A1. Sep 21, 2017.<a href="https://www.google.com/patents/US20170269095A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> <a href="https://patents.google.com/?inventor=Paul+C.+Lee">Paul C. Lee</a>. “Nanoparticle probes and methods of making and use thereof.” US20180000972A1. Jan 04, 2018.<a href="https://www.google.com/patents/US20180000972A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned anti-ICAM1 VHH antibody biotinylated at the C-terminus was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Hernández P, Gorrochategui J, Primo D, et al. Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry[J]. SLAS TECHNOLOGY: Translating Life Sciences Innovation, 2017, 22(3): 325-337.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28340541" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs generated anti-CD3×CD123 bispecific antibody. <ul class="ullist disc"> <li> Iz S G, Inevi M A, Metiner P S, et al. A biodesign approach to obtain high yields of biosimilars by anti-apoptotic cell engineering: A case study to increase the production yield of anti-TNF alpha producing recombinant CHO cells[J]. Applied biochemistry and biotechnology, 2018, 184(1): 303-322.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28685239" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned humanized anti-TNFα mAb, suspension culture, and serum-free medium adapted stable CHO cell line were obtained from Creative Biolabs. <ul class="ullist disc"> <li> Liu, Duan, et al. "Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics." Translational psychiatry 8.1 (2018): 10.<a href="https://www.nature.com/articles/s41398-017-0056-8" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned Creative Biolabs generated recombinant human DEFB1 protein to neutralize lipopolysaccharide (LPS) and validate the biosynthesis of KYN in monocytic cells. <ul class="ullist disc"> <li> Wang, Chao, Veronique Beiss, and Nicole F. Steinmetz. "Cowpea mosaic virus nanoparticles and empty virus-like particles show distinct but overlapping immunostimulatory properties." Journal of virology 93.21 (2019): e00129-19.<a href="https://jvi.asm.org/content/93/21/e00129-19" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the eCPMV/I formulation was produced by Creative Biolabs through Sf9 insect cells expression system. <ul class="ullist disc"> <li> Begemann, Anaïs, et al. "Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes." Molecular Medicine 25.1 (2019): 6.<a href="https://link.springer.com/article/10.1186/s10020-019-0073-6" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned mutagenesis of human SCN2A, RefSeq NM_021007, SCN1B and SCN2B was performed by Creative Biolabs and verified by sequencing. <a name="_SECTION_9:_Other"></a> SECTION 9: Other Services and Products<a href="Peer-Reviewed-Publications.html#pubtop" rel="nofollow">[Top]</a> Creative Biolabs is dedicated to offering a full spectrum of services covering basic scientific research and biopharmaceutical requirements. Our services are not limited to those listed above, but also include other basic reagents and technologies such as bioconjugation and tumor specimen preparation, etc. We are committed to sharing our knowledge to accelerate and maximize the success of your research & discovery projects. <ul class="ullist disc"> <li> Du Z Q, Yang C X, Rothschild M F, et al. Novel microRNA families expanded in the human genome[J]. BMC genomics, 2013, 14(1): 98.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23402294" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described Creative Biolabs performed FISH on a normal primary neonatal dermal fibroblast cell line of European origin following standard procedures with short probe length (~1 kb). <ul class="ullist disc"> <li> Genetic Engineering & Biotechnology News (2009): GEN., Volume 29, Issues 1-8 (pp48, pp56). NY, USA: GEN Pub. Inc.<a href="http://www.liebertpub.com/overview/genetic-engineering-and-biotechnology-news/17/" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Marzioni M, Germani U, Agostinelli L, et al. PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: Perspectives in the diagnosis of pancreatic cancer[J]. Digestive and Liver Disease, 2015, 47(2): 138-143.<a href="https://www.ncbi.nlm.nih.gov/pubmed/25454709"> </a> </li> </ul> These papers mentioned that <a href="/fluorescent-in-situ-hybridization-FISH.html">Fluorescent in Situ Hybridization (FISH)</a>was performed according to the instructions of Creative Biolabs. <ul class="ullist disc"> <li> Scherthan H. Imaging of chromosome dynamics in mouse testis tissue by immuno-FISH[M]//Meiosis. Humana Press, New York, NY, 2017: 231-243.<a href="https://www.ncbi.nlm.nih.gov/pubmed/28349399" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned directly fluorochrome-labeled probes of different complexities are available at Creative Biolabs. <ul class="ullist disc"> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." US8669239 B2. Mar 11, 2014<a href="https://www.google.com/patents/US8669239" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." EP2412383 A1. Feb 1, 2012<a href="https://www.google.com/patents/EP2412383A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." US8106004 B2. Jan 31, 2012<a href="https://www.google.com/patents/US8106004B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." US8975037 B2. Mar 10, 2015<a href="https://www.google.com/patents/US8975037" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." US20100105610 A1. Apr 29, 2010<a href="https://www.google.com/patents/US20100105610" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." US20080050362 A1<a href="https://www.google.com/patents/US20080050362" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." EP 2074209 A2. Jul 1, 2009<a href="https://www.google.com/patents/EP2074209A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." CA 2658786 A1. Jan 31, 2008<a href="https://www.google.com/patents/CA2658786A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Hendrix, Mary Jessica, et al. "Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells." WO2008014426 A2. Jan 31, 2008. <a href="https://www.google.com/patents/WO2008014426A2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs provided a breast carcinoma progression TMA used for immunohistochemical staining. <ul class="ullist disc"> <li> Gregg J L, Brown K E, Mintz E M, et al. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection[J]. BMC cancer, 2010, 10(1): 165.<a href="http://www.ncbi.nlm.nih.gov/pubmed/20426842" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the commercially available prostate tissue microarrays (TMAs) used for immunohistochemistry (IHC) and scoring of TMAs were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Chaerkady R, Harsha H C, Nalli A, et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma[J]. Journal of proteome research, 2008, 7(10): 4289-4298.<a href="http://www.ncbi.nlm.nih.gov/pubmed/18715028" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described IHC for myeloid-associated differentiation marker was carried out using tissue microarrays provided by Creative Biolabs. <ul class="ullist disc"> <li> Chaerkady R, Thuluvath P J, Kim M S, et al. 18 O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma[J]. Clinical proteomics, 2008, 4(3): 137.<a href="http://www.ncbi.nlm.nih.gov/pubmed/20357908" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the formalin fixed and paraffin embedded tissue microarrays used for immunohistochemical labeling were obtained from Creative Biolabs. <ul class="ullist disc"> <li> Harris M A, Yang H, Low B E, et al. Cancer stem cells are enriched in the side population cells in a mouse model of glioma[J]. Cancer research, 2008, 68(24): 10051-10059.<a href="http://www.ncbi.nlm.nih.gov/pubmed/19074870" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the human glioma tissue arrays used for Immunohistochemistry were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Li W, Tai Y, Zhou J, et al. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis[J]. Cell cycle, 2012, 11(12): 2348-2358.<a href="http://www.ncbi.nlm.nih.gov/pubmed/22672904" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described the formalin-fixed and paraffin-embedded tumor specimens used for IHC staining were provided by Creative Biolabs. <ul class="ullist disc"> <li> Postovit L M, Margaryan N V, Seftor E A, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells[J]. Proceedings of the National Academy of Sciences, 2008, 105(11): 4329-4334.<a href="https://www.ncbi.nlm.nih.gov/pubmed/18334633" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned a breast carcinoma progression tissue microarray used for immunohistochemical staining for Nodal was supplied by Creative Biolabs. <ul class="ullist disc"> <li> Pei Z, Fraisl P, Shi X, et al. Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer[J]. PLoS One, 2013, 8(7): e69392.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23936004" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the normal human lung and 67 different lung tumors used for immunohistochemistry were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Chow K H, Park H J, George J, et al. S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma[J]. Cancer research, 2017: canres. 1294.2017.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28807938" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the tissue microarrays were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Telikicherla D, Marimuthu A, Kashyap M K, et al. Overexpression of ribosome binding protein 1 (RRBP1) in breast cancer[J]. Clinical proteomics, 2012, 9(1): 7.<a href="http://www.ncbi.nlm.nih.gov/pubmed/22709790" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned breast cancer progression TMA was purchased from Creative Biolabs. <ul class="ullist disc"> <li> Chenguang Wang, Jie Zhou. “Compositions and methods for treating cancer with aberrant lipogenic signaling.” WO 2014004054 A1. Jan 3, 2014<a href="https://www.google.com/patents/WO2014004054A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Chenguang Wang, Jie Zhou. “Compositions and methods for treating cancer with aberrant lipogenic signaling.” CN104662028 A. May 27, 2015<a href="https://www.google.com/patents/CN104662028A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Chenguang Wang, Jie Zhou. “Compositions and methods for treating cancer with aberrant lipogenic signaling.” EP2864339 A1. Apr 29, 2015<a href="https://www.google.com/patents/EP2864339A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> <li> Wang, Chenguang, and Jie Zhou. "Compositions and methods for treating cancer with aberrant lipogenic signaling." US9988403B2. Jun 05, 2018.<a href="https://www.google.com/patents/US9988403B2"> </a> </li> <li> Wang, Chenguang, and Jie Zhou. "Compositions and methods for treating cancer with aberrant lipogenic signaling." US9750758B2. Sep 05, 2017.<a href="https://www.google.com/patents/US9750758B2" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> These patents mentioned Creative Biolabs served Formalin-fixed and paraffin-embedded tumor specimens for IHC purpose. <ul class="ullist disc"> <li> American Association for Cancer Research, William H. Donner Foundation (2008). Cancer Research (pp142). Baltimore, USA: Waverly Press<a href="https://fconline.foundationcenter.org/fdo-grantmaker-profile/?key=DONN004" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This chapter mentioned the normal human lung and 67 different lung tumors were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Sun, Zhijian, et al. “Kinds of human interleukin-2 fusion proteins and their use against human epithelial cell adhesion molecule single-chain antibody.” CN108503714A. Sep 07, 2018.<a href="https://www.google.com/patents/CN108503714A" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned the huKS_IL2 and MTllO utilized in T cell proliferation assays were supplied by Creative Biolabs. <ul class="ullist disc"> <li> Weidanz, Jon. “Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer.” WO2018140525A1. Aug 02, 2018.<a href="https://www.google.com/patents/WO2018140525A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned the immunogen was prepared with Magic™ adjuvant supplied by Creative Biolabs. <ul class="ullist disc"> <li> Bu Y, Yoshida A, Chitnis N, et al. A PERK–miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival[J]. Nature cell biology, 2018, 20(1): 104.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29230015" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned m7GTP beads used for immunoprecipitation was provided by Creative Biolabs. <ul class="ullist disc"> <li> Mallavia B, Recio C, Oguiza A, et al. Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis[J]. The American journal of pathology, 2013, 182(5): 1910-1921.<a href="http://www.ncbi.nlm.nih.gov/pubmed/23597852" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper described a cell-permeable peptide containing the hydrophobic region of the signal peptide of Kaposi fibroblast growth factor and a single NLS from NF-kB was synthesized and cyclized (intrachain disulfide bond between cysteines inserted in the NLS motif) by Creative Biolabs. <ul class="ullist disc"> <li> Luloh, Klaus Peter, et al. "HOMOGENOUS AND HETEROGENEOUS ASSAYS AND SYSTEMS FOR DETERMINATION OF OCULAR BIOMARKERS." US20180074074A1. Mar 15, 2018.<a href="https://www.google.com/patents/US20180074074A1" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This patent mentioned gold particles are commercially available at different sizes from Creative Biolabs. <ul class="ullist disc"> <li> Reineck P, Gibson B C. Near‐Infrared Fluorescent Nanomaterials for Bioimaging and Sensing[J]. Advanced Optical Materials, 2017, 5(2): 1600446.<a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/adom.201600446" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned that custom bioconjugation services for fluorophores (and sometimes fluorescent beads) are commercially available at Creative Biolabs. <ul class="ullist disc"> <li> Davis C E, Patel M K, Miller J R, et al. Effects of phospholemman expression on swelling-activated ion currents and volume regulation in embryonic kidney cells[J]. Neurochemical research, 2004, 29(1): 177-187.<a href="http://www.ncbi.nlm.nih.gov/pubmed/14992277" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned the ﬁbronectin-coated coverslips used for cell culture was provided by Creative Biolabs. <ul class="ullist disc"> <li> Iz S G, Inevi M A, Metiner P S, et al. A biodesign approach to obtain high yields of biosimilars by anti-apoptotic cell engineering: A case study to increase the production yield of anti-TNF alpha producing recombinant CHO cells[J]. Applied biochemistry and biotechnology, 2018, 184(1): 303-322.<a href="http://www.ncbi.nlm.nih.gov/pubmed/28685239" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned humanized anti-TNFα mAb, suspension culture, and serum-free medium adapted stable CHO cell line were obtained from Creative Biolabs. <ul class="ullist disc"> <li> Singh S, Murillo G, Chen D, et al. Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3[J]. Breast cancer: basic and clinical research, 2018, 12: 1178223417750858.<a href="http://www.ncbi.nlm.nih.gov/pubmed/29434474" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned pCDis-play-3M phagemid and STAT3 protein used in immunoprecipitation were purchased from Creative Biolabs. <ul class="ullist disc"> <li> Geldenhuys, Werner J., et al. "Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand." Communications Chemistry 2.1 (2019): 1-9.<a href="https://www.nature.com/articles/s42004-019-0172-x" target="_blank"><img border="0" width="14" height="19" src="static/img/arrpub.png" /></a> </li> </ul> This paper mentioned SPR studies were done by CreativeBiolabs. </div> <script type="text/javascript"> function Trim_string(str){ return str.replace(/[ ]/g,""); } $(document).ready(function() { $(".sectionLinks a").click(function(){ var Duanstring=Trim_string($(this).text()); $(".publicationTit").each(function(){ if (Trim_string($(this).text()).indexOf(Duanstring)>-1){ $(this).parent(".section_site").css("padding-top","120px"); } else{ $(this).parent(".section_site").css("padding-top","0px"); } }) }) }) </script> All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications. </div> <div class="col-md-3"> <a name="OnlineInquiry"></a> <div class="rightcontact inquiry_bg_small"> <div class="rig_tit">Online Inquiry</div> <link rel="preconnect" href="https://www.recaptcha.net" /> <style type="text/css">.grecaptcha-badge { opacity: 0; }</style> <script src="https://www.recaptcha.net/recaptcha/enterprise.js?render=6LdtbowmAAAAABp2LeBkVvRNBQvLXkSG5aExNWHk"></script> <script> function grecaptchaFormBinding(formName, callback, event, action='submit_form') { if (event != undefined) { event.preventDefault ? event.preventDefault() : (event.returnValue = false); } var _form = document.forms[formName]; if (_form != undefined) { grecaptcha.enterprise.ready(function () { grecaptcha.enterprise.execute('6LdtbowmAAAAABp2LeBkVvRNBQvLXkSG5aExNWHk', { action: action.length > 0 ? action : 'submit_form' }).then(function (token) { if (_form['g-recaptcha-response'] === undefined) { var _response_input = document.createElement('input'); _response_input.setAttribute('type', 'hidden'); _response_input.setAttribute('name', 'g-recaptcha-response'); _response_input.setAttribute('readonly', 'readonly'); _response_input.setAttribute('value', token); _form.appendChild(_response_input); } else { _form['g-recaptcha-response'].value = token; } if (callback != undefined) { callback(); } }); }); } } </script>  <script> window.addEventListener('load', function () { jQuery(document).ready(function () { jQuery("#formID").validationEngine("attach", { promptPosition: "bottomLeft", scroll: false, autoHidePrompt: true, autoHideDelay: 3000 }); // binds form submission and fields to the validation engine jQuery("#formID").validationEngine(); $("#formID").bind("jqv.form.validating", function (event) { $("#hookError").html(""); }); $("#formID").bind("jqv.form.result", function (event, errorFound) { if (errorFound) { $("#hookError").append("There is some problems with your form"); } }); $("#formID").submit(function (e) { if ($('#formID').validationEngine('validate')) { $(this).find(":submit").prop("disabled", true); grecaptchaFormBinding('orderform', function () { document.forms['orderform'].submit(); }, e); } //$(this).find(":submit").prop("disabled", false); e.preventDefault ? e.preventDefault() : (e.returnValue = false); return false; }); }); }); </script> <form role="form" id="formID" name="orderform" class="Inquiry_form" method="post" action="/form/pub.aspx" autocomplete="off"> <input type="hidden" id="inquirytoken" name="inquirytoken" value="4w1Qcfz9" /> <input type="hidden" name="inquiryType" value="service"> <input type="hidden" name="cat" value=""> <input type="hidden" name="pn" value="" /> <input type="hidden" name="pn_url" value="" /> <div class="row"> <div class="col-md-12"> <label for="Phone">Name</label> <input type="text" placeholder="Name" name="I_Name" id="I_Name" /> </div> <div class="col-md-12"> <label for="Phone">* Phone</label> <input type="text" name="I_Phone" id="I_Phone" placeholder="Phone" class="form-control input-md inputborderSecond validate[required] text-input" /> </div> <div class="col-md-12"> <label for="Email">* Email</label> <input type="text" placeholder="Email" name="email" id="email" class="form-control input-md form-control inputborderSecond validate[required,custom[email]] text-input" /> </div> <div class="col-md-12"> <label>* Products or Services Interested:</label> <input type="text" name="I_Subject" id="I_Subject" placeholder="Products or Services Interested" value="Peer-Reviewed Publications" class="form-control input-md inputborderSecond validate[required] text-input" /> </div> <div class="col-md-12"> <label>Project Description</label> <textarea name="I_Message{EXT:[IEXT_Description]}" id="I_Message" placeholder="Project Description" cols="40" rows="4"></textarea> </div> <div class="col-md-12"> <input type="hidden" name="I_Codenumber" value="" /> <input type="hidden" name="I_From Codenumber" value="" /> <button class="submit" type="submit">Send</button> <script src="https://static.creative-biolabs.com/_noindex/google-verification/verification.js" type="text/javascript"></script> <div style="clear: both;"></div> </div> </div> </form> </div> <div class="rightcontact"> <div class="rig_tit">CONTACT US</div> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="border:0px;"> <tr> <td valign="top"></td> <td valign="top">USA: Europe: Germany: </td> </tr> <tr> <td valign="top"></td> <td valign="top"> Call us at: USA: UK: Germany: </td> </tr> <tr> <td valign="top"></td> <td valign="top"> Fax: </td> </tr> <tr> <td valign="top"></td> <td valign="top"> Email: <a cbl-email class="a_link"></a> </td> </tr> </table> </div> </div> </div> <div class="promisebottom">Our customer service representatives are available 24 hours a day, 7 days a week. <a href="contactus.html" class="signup">Contact Us</a></div> <div class="contact_bottom"> <div class=" bottom_colum"> <div class="content-width"> <ul> <li> Services <ul> <li><a href="/phage-display-library-construction.html">Phage Display Library Construction</a></li> <li><a href="/phage-display-library-screening.html">Phage Display Library Screening</a></li> <li><a href="/Hybridoma-Services.html">Hybridoma Services</a></li> <li><a href="/Membrane-Protein-Service.html">Magic™ Anti-Membrane Protein Antibody Discovery</a></li> <li><a href="/Production-of-Anti-idiotype-Antibody.html">Anti-idiotype Antibody Discovery</a></li> <li><a href="/Nanobody-Single-Domain-Antibody.html">Single Domain Antibody (sdAb) Discovery</a></li> <li><a href="/Native-TM-Antibody-Discovery-Service.html">Native™ Antibody Discovery</a></li> <li><a href="/Next-Generation-Antibody-Sequencing.html">De Novo Antibody Sequencing</a></li> <li><a href="/antibody-humanization.html">Antibody Humanization</a></li> <li><a href="/antibody-affinity-maturation.html">Antibody Affinity Maturation</a></li> <li> <a href="/Custom-antibody-services-for-post-translational-modification-specific-antibody-discovery.html">Post-Translational Modification (PTM) Specific Antibody Discovery</a></li> </ul> </li> <li> Platforms <ul> <li><a href="Phage-Display-Platform.html">Phage Display Platform</a></li> <li><a href="Membrane-Protein-Platform.html">Membrane Protein Platform</a></li> <li><a href="hyperdoma-a-high-throughput-hybridoma-generation-platform.html">Hyperdoma™ Platform</a></li> <li><a href="b-cell-sorting-platform.html">B-Cell Sorting Platform</a></li> </ul> Help & Support <ul>  <li><a href="/faq.htm">Frequently Asked Questions (FAQs)</a></li> <li><a href="/support-documents.html">Support Documents</a></li> <li><a href="/knowledge-center.html">Knowledge Center</a></li> <li><a href="/newsletter.aspx">Newsletter</a></li> <li><a href="/protocol.html">Protocol</a></li> <li><a href="/literature.html">Literature</a></li> </ul> </li> <li class="bottom_contac_info"> Contact us USA Tel: Fax: Email: <a cbl-email class="a_link"></a> UK Tel: Email: <a cbl-email class="a_link"></a> Germany Tel: Email: <a cbl-email class="a_link"></a> </li> <li> Subscribe to Our Newsletter for Updates: <input type="text" class="letterinput" id="subscribeemail" placeholder="email@example.com"> <button type="button" class="newsletterbutton" onclick="javacript:subscribe('subscribeemail','Creative Biolabs','www.creative-biolabs.com')">Sign Up Now</button> <div class="iso"> <img src="https://www.cblcdn.com/images/ISO90012015.png" srcset="https://www.cblcdn.com/images/ISO90012015.webp 1x, https://www.cblcdn.com/images/ISO90012015.webp 2x, https://www.cblcdn.com/images/ISO90012015.webp 3x" width="200" alt="ISO 9001 Certified - Creative Biolabs Quality Management System" loading="lazy"> </div> </li> </ul> </div> </div> <script> window.addEventListener('load', function () { $(function () { var bottomspan=$(".bottom_tit span"); bottomspan.on("click",function(){ $(this).toggleClass("arrw"); $(this).parent(".bottom_tit").siblings("ul").toggle(100); }) }) }) </script> <div class="clear"></div> </div> <div class="indexfoot"> <div class="content-width"> <div class="col-md-9 col-sm-9 col-lg-9"> © 2024 Creative Biolabs. | <a href="contactus.html">Contact Us</a> </div> <link href="https://static.creative-biolabs.com/icon/style.css?v=1.0.202402" rel="stylesheet" type="text/css" /> <div class="col-md-3 col-sm-3 col-lg-3"> <a target="_blank" href="https://www.facebook.com/CreativeBiolabs" data-wow-duration="2s" aria-label="Learn more from facebook"></a> <a target="_blank" href="https://twitter.com/CreativeBiolabs" aria-label="twitter"></a> <a target="_blank" href="http://www.linkedin.com/company/creative-biolabs/" aria-label="Learn more from linkedin"></a> <a target="_blank" href="https://www.youtube.com/@CreativeBiolabs" aria-label="Learn more from youtube"></a> <a target="_blank" href="/blog/" aria-label="Learn more from blog"></a> </div> </div> </div>  <link rel="stylesheet" type="text/css" href="static/css/public-new.css?t=D20190703" async> <link rel="stylesheet" type="text/css" href="static/css/bootstrap.min.css?t=D20190703" async> <link rel="stylesheet" type="text/css" href="static/css/fontawesome-all.min.css?t=D20190703" async> <script src="static/js/jquery-3.1.1.min.js"></script> <link href="/static/css/validationEngine.jquery.css" rel="stylesheet" async/> <script src="/static/js/jquery.validationEngine-en.js" async></script> <script src="/static/js/jquery.validationEngine.js" async></script> <script src="https://static.creative-biolabs.com/js/ahref.js" type="text/javascript" defer></script> <script> const loadContact = () => { if (typeof contactInformation !== 'undefined') new contactInformation({ opts: { messTags: ['cbl-addr-usa', 'cbl-tel-usa1478', 'cbl-tel-usa2254', 'cbl-tel-usa5530', 'cbl-tel-usa9819', 'cbl-fax', 'cbl-email', 'cbl-addr-uk', 'cbl-tel-uk', 'cbl-addr-germany', 'cbl-tel-germany' ], mainFix:"www.creative-biolabs.com" } }); } </script> <script src="https://www.cblcdn.com/_noindex/contact/base64Decryption.js" onload="loadContact();" async></script> <script src="static/js/navimenu.js" type="text/javascript" async></script> <script src="static/js/auto.js" type="text/javascript" async></script> <script src="static/js/base.js?v=1.0.05302" type="text/javascript" async></script> <script src="static/js/scrolltopcontrol.js" type="text/javascript" defer></script> <script> privacy_policy_config = {name: "3g7R9s", debug: true, url: "https://go.creative-biolabs.com/privacy-policy?website=com&domain=www.creative-biolabs.com&contact=marketemail_7b95a2ac8713cd7a3fdc04ba95ccdf9d"}; </script> <script src="https://www.cblcdn.com/_noindex/jquery.privacy.policy-v.js?v=1.0.202402" defer></script> </body> </html>